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Summary 
 
 Gene expression regulation is a dynamic and multi-step process, 
in which transcription plays a major role. Transcription initiation depends 
on binding of transcription regulators to DNA elements located in promoter 
or enhancer regions, a process often controlled by signalling pathways. 
One such pathway is regulated by Rac1, a member of the Rho family of 
small GTPases involved in cell proliferation, adhesion and migration. In 
this work, novel links between Rac1 signalling and transcriptional 
regulation in colorectal tumour cells are described. First, it is shown that 
Rac1 activation leads to PAK1-mediated phosphorylation of the 
transcriptional repressor BCL-6 in colorectal cancer cells, inactivating its 
repressor function. In the presence of active Rac1, BCL-6 redistribution 
within the nucleus, a reduction in its affinity to chromatin and increased 
expression of the endogenous target genes NFKB1 and CD44, and of a 
BCL-6-controlled luciferase reporter construct were observed. Next, it was 
found that Rac1 signalling promotes gene transcription by inducing a 
transcriptional switch from the repressor BCL-6 to the activator STAT5A at 
the promoter of certain target genes. Using chromatin 
immunoprecipitation, it is demonstrated in different colorectal cell lines 
that active Rac1 promotes release of BCL-6 with concomitant nuclear 
translocation and binding of STAT5A at the same promoter site. Three 
endogenous cell-cycle-related genes (CCND2, CDKN2B, SUMO1) were 
identified to be inversely regulated by BCL-6 and STAT5A and shown to 
respond to Rac1 signalling with promoter occupancy switches that 
correlate directly with changes in their expression levels.  
 This work provides new mechanistic insights into how Rac1 
signalling modulates gene transcription through the switching between 
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transcription factors and contributes to uncovering the implications of 
deregulated Rac1 activity in cancer.  
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Sumário 
 
 A expressão génica é um processo essencial à vida, determinando 
a forma como todas as funções biológicas são executadas, pelo que 
qualquer alteração à forma como os genes são expressos tem 
implicações para a célula e encontra-se muitas vezes ligada à ocorrência 
de doenças (Maston et al., 2006), como por exemplo o cancro. A 
expressão génica é um processo que se desenrola em vária etapas, 
começando na transcrição do gene, passando pelo processamento do 
mRNA (por exemplo, no splicing e/ou na poliadenilação), pelo transporte 
do mRNA para o citoplasma, pela sua tradução e mesmo pelas 
modificações pós-transducionais que conferem à proteína resultante a 
sua forma e funcionalidades finais (Singer and Green, 1997; Maston et 
al., 2006). Embora a regulação apertada de cada um destes passos, bem 
como a sua sincronia, seja fundamental para o funcionamento correcto da 
célula, muitos autores defendem que o ponto crítico na regulação da 
expressão génica se encontra no início da transcrição (Maston et al., 
2006; Hager et al., 2009). 
 O início da transcrição depende da ligação de factores 
reguladores, activadores ou repressores, a sequências de DNA 
particulares localizadas no promotor do gene ou em regiões vizinhas 
designadas vulgarmente por enhancer regions. Por sua vez, a activação 
destes factores de transcrição é, em grande parte, controlada por vias de 
sinalização celular que respondem a estímulos intracelulares e 
extracelulares de ordem diversa (Orphanides and Reinberg, 2002; 
Venters and Pugh, 2009). Algumas dessa vias de sinalização são 
moduladas por Rac1, um membro da família Rho de GTPases de baixa 
massa molecular, que está envolvido na regulação de diversos processos 
celulares, incluíndo a proliferação, sobrevivência, adesão e migração 
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celulares. A desregulação da expressão e/ou actividade de Rac1 pode 
resultar numa sinalização celular anormal e tem sido frequentemente 
associado a condições patológicas diversas (Bosco et al., 2009).  
 Neste trabalho são descritos novos pontos de ligação entre a 
sinalização de Rac1 e a regulação transcricional em linhas celulares de 
cancro colorectal.  
 Em primeiro lugar, demonstrou-se que o repressor transcricional 
BCL-6 é regulado negativamente pela sinalização de Rac1. Para tal, 
utilizou-se como repórter uma construção do gene da luciferase sob o 
controlo dum promotor artificial responsivo a BCL-6. Verificou-se que em 
células colorectais DLD-1 a actividade deste repórter de luciferase 
aumentava na presença de Rac1 constitutivamente activo e que, pelo 
contrário, era reprimida na presença de um inibidor da activação 
endógena de Rac1 (NSC23766). Adicionalmente, verificou-se que a 
expressão de genes endógenos regulados por BCL-6, como NFKB1 e 
CD44, aumentava ou diminuía de acordo com a activação de Rac1. Em 
seguida, verificou-se que a activação de Rac1 também afectava a 
distribuição sub-nuclear de BCL-6, passando de uma localização 
característica em foci nucleares para uma distribuição difusa e mais 
homogénea pelo nucleoplasma. Este resultado foi corroborado por 
ensaios de fraccionamento celular que mostraram que, na presença de 
Rac1, o factor BCL-6 perde a sua afinidade para o DNA, ocorrendo uma 
transição de BCL-6 da fracção nuclear insolúvel, ligada à cromatina, para 
uma fracção nuclear solúvel. Seguidamente, analisou-se qual o 
mecanismo que podia estar subjacente à inactivação de BCL-6 por parte 
de Rac1. Após se ter verificado que não se tratava de uma interacção 
directa entre as duas proteínas, avaliou-se a participação de outras 
proteínas, nomeadamente, outras Rho GTPases (RhoA, Cdc42, Rac1b) e 
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efectores de Rac1 (JNK, PAK), através de ensaios de luciferase. 
Constatou-se que apenas a cinase PAK tinha um efeito semelhante ao 
induzido por Rac1 e que a sua activação era necessária para produzir as 
alterações observadas na actividade de BCL-6. Por último,     
demonstrou-se que a isoforma alfa da cinase PAK (PAK1) fosforila 
directamente BCL-6 in vitro e in vivo, identificando-se esta cinase como o 
mediador da regulação negativa de Rac1 sobre BCL-6 em células 
colorectais. Desta forma, caracterizou-se  uma nova via de sinalização – 
Rac1/PAK1/BCL-6 – que relaciona Rac1 com a regulação transcricional. 
 Sabia-se de estudos anteriores que, em células epiteliais, a 
sinalização de Rac1 é necessária à activação de outros factores de 
transcrição, nomeadamente do activador trancricional STAT5. 
(Kawashima et al., 2006), Curiosamente, as sequências de DNA 
reconhecidas por BCL-6 são bastante semelhantes às sequências de 
ligação de STAT5 (Dent et al., 1997; Horvath, 2000), pelo que colocámos 
a hipótese de BCL-6 e STAT5 poderem desempenhar papéis opostos na 
regulação transcricional de alguns genes alvo e a sinalização de Rac1 
poder estar a coordenar a troca (switch) entre estes dois factores a nível 
dos promotores desses mesmos genes. Assim, utilizou-se a técnica de 
imunoprecipitação da cromatina (ChIP) para avaliar a ligação de STAT5 e 
BCL-6 ao promotor da construção repórter acima referida e mostrou-se 
que, de facto, a activação de Rac1 promove a remoção de BCL-6 do 
promotor, ao mesmo tempo, que aumenta a ligação de STAT5. 
Paralelamente, verificou-se que, em células colorectais, a activação de 
Rac1 estimula a translocação nuclear de STAT5 e a sua ligação à 
cromatina. Para entender a relevância fisiológica deste switch entre   
BCL-6 e STAT5 caracterizaram-se os níveis de activação endógenos de 
Rac1, PAK1, STAT5 e BCL-6 em várias linhas celulares colorectais, com 
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vista a eleger os modelos celulares mais adequados para a identificação 
de genes alvo da nova via de sinalização Rac1/PAK1/BCL-6/STAT5. 
Tendo-se constatado que em duas dessas linhas (DLD-1 e HT29) o 
estado de activação da via de sinalização Rac1/PAK1 se correlacionava 
com o nível de fosforilação de BCL-6 e STAT5, procedeu-se ao 
silenciamento, por interferência de RNA (RNAi), da expressão endógena 
de BCL-6 ou STAT5 e analisou-se, por PCR em tempo-real, o efeito da 
supressão destes factores na expressão de 84 genes, relacionados com 
o ciclo celular, presentes num array comercial. Desta forma, identificaram-
se três genes (CCND2, CDKN2B, SUMO1) inversamente regulados por 
BCL-6 e STAT5 e confirmou-se por ChIP que ambos os factores de 
transcrição se ligam aos promotores destes genes. Além disso, 
demonstrou-se que estes genes respondem à sinalização de Rac1 e 
PAK1 com um switch entre STAT5/BCL-6 na ocupação do promotor e 
que tal se correlaciona directamente com as alterações observadas ao 
nível da sua expressão.  
 Em conclusão, os resultados expostos nesta tese proporcionam 
um melhor entendimento dos mecanismos moleculares através dos quais 
a sinalização via Rac1 consegue modular a expressão génica, 
contribuindo com novos dados para o esclarecimento das implicações da 
desregulação da actividade de Rac1 no cancro. 
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 All living cells need to constantly assess the surrounding 
environment to communicate and collect information about their state and 
requirements in order to make accurate decisions. Thus, the ability to 
convert extracellular signals into specific internal cellular responses is 
fundamental for cell survival and proper development (Karin, 1992; 
Downward, 2001).  
Signal transduction is the field that studies the mechanisms by 
which biological information is transferred, from the level of individual cells 
to the whole organism. In general, these include a multitude of sequential 
biochemical reactions and interacting molecular cascades – signalling 
transduction pathway – that are initiated with the activation of a specific 
cell-surface receptor by an extracellular stimulus. The signal is then 
conducted into the cell, from the receptor to intermediate molecules 
through changes in their conformation and activity, until the final target in 
the cytoplasm or in the nucleus is reached and an outcome for the cell is 
produced (Persidis, 1998; Downward, 2001).  
Due to the diversity and complexity of signalling pathways, their 
influence covers almost every aspect of cell life, including cell division, 
apoptosis, cytoskeletal organization, metabolism and gene expression 
(Pawson and Nash, 2000). The modulation of gene expression is an 
important consequence since it can generate long-lasting responses that, 
in turn, will affect several biological functions (Karin, 1992). 
The relationship between signalling dysfunctions and several 
diseases, such as cancer, does not surprise and is widely recognized, 
increasing the interest and possible impact of dissecting and 
understanding these cellular networks (Karin, 1992; Persidis, 1998; 
Downward, 2001). A good example of this straight connection is the Ras 
superfamily of small guanosine triphosphatases (GTPases). On one hand, 
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these proteins are key elements of several signalling pathways and on the 
other hand play crucial roles in human oncogenesis, in particularly their 
founding members, the Ras (Rat sarcoma) proteins (Hernández-Alcoceba 
et al., 2000; Wennerberg et al., 2005). 
 
1.1. Rho GTPases 
 
 Rho (Ras homologous) GTPases form a subgroup of the Ras 
superfamily of small GTPases (Wennerberg et al., 2005), highly 
conserved amongst all eukaryotic organisms, from yeasts, to plants, up to 
mammals (Wherlock and Mellor, 2002; Boureux et al., 2007). Similar to 
Ras, they are intracellular signalling molecules that can respond to diverse 
stimuli and regulate a wide variety of cellular processes including cell size, 
proliferation, survival, cell adhesion, cell polarity, membrane trafficking, 
cytoarchitecture and transcriptional activation (Van Aelst and D’Souza-
Schorey, 1997; Etienne-Manneville and Hall, 2002; Jaffe and Hall, 2005). 
The Rho-family is composed by monomeric G proteins of low 
molecular weight (~20-30 kDa) (Van Aelst and D’Souza-Schorey, 1997; 
Cotteret and Chernoff, 2002) with the capacity to bind with high affinity to 
the guanine nucleotides, guanosine diphosphate (GDP) or guanosine 
triphosphate (GTP) and to hydrolyze GTP (GTPase activity) (Vetter and 
Wittinghofer, 2001). This attribute is due to a conserved element within 
Ras-like proteins, the GTPase domain, that comprises a set of G-boxes 
with consensus amino acid sequences for GTP binding and hydrolysis 
(Vetter and Wittinghofer, 2001; Wennerberg et al., 2005). The presence of 
a Rho-specific insert in the GTPase domain, involved in the recognition of 
effector proteins and regulators, distinguishes Rho-family members 
(Wennerberg and Der, 2004; Boureux et al., 2007). Another particular 
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feature of this family is that most members undergo post-translational 
modifications at their carboxyl (C-) terminus by the addition of prenyl 
groups (such as farnesyl or geranylgeranyl). These function as lipid 
anchors that facilitate association with membranes and thus subcellular 
localization, essential for Rho GTPases biological functions (Wennerberg 
and Der, 2004; Wennerberg et al., 2005; Bos et al., 2007).  
 
1.1.1. Organization and regulation  
 
Currently, after phylogenetic and evolutionary studies, the human 
Rho-family counts 22 members, 2 of which being variants of Rac1 and 
Cdc42 originated by alternative splicing, distributed into 8 subfamilies 
according to sequence similarity: Rho (RhoA, RhoB, RhoC), Rac (Rac1, 
Rac1b [Rac1 splice variant], Rac2, Rac3, RhoG), Cdc42 (Cdc42, G25K 
[Cdc42 brain-specific C-terminal splice variant], TC10/RhoQ, TCL/RhoJ), 
RhoD/F (RhoD, Rif/RhoF), Rnd (Rnd1, Rnd2, Rnd3/RhoE), RhoU/V 
(Wrch-1/RhoU, Chp/RhoV), RhoH and RhoBTB (RhoBTB1, RhoBTB2) 
(Fig. 1) (Aspenström et al., 2007; Boureux et al., 2007). Out of these 
subfamilies, Rnd, Wrch-1/Chp, RhoH and RhoBTB have particularities in 
terms of structure, function and regulation that make them atypical 
compared to the Rho, Rac (with exception of Rac1b), Cdc42 and 
RhoD/RhoF subfamilies that follow the classical activation cycle (see 
below) (Aspenström et al., 2007).   
 Like other small GTPases, Rho proteins function as molecular 
switches, cycling between an inactive (GDP-bound) and an active (GTP-
bound) conformational state (Vetter and Wittinghofer, 2001; Etienne-
Manneville and Hall, 2002). These conformational changes produce 
alterations in their binding affinity for downstream effectors or regulatory 
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proteins and are mainly localized in two short and flexible loop structures 
of the GTPase domain, designated as Switch I and Switch II (Vetter and 
Wittinghofer, 2001; Wennerberg et al., 2005). Hence, the active 
conformation favours the interaction with target proteins, inducing 
downstream signalling events that cease with the hydrolysis of GTP and 
the return of the GTPase to its inactive state (Bishop and Hall, 2000; 
Hernández-Alcoceba et al., 2000; Etienne-Manneville and Hall, 2002).  
 
 
Figure 1: Phylogenetic tree representation of the Rho GTPases family. The 
22 members are distributed into 8 groups – Rho, Rac, Cdc42, RhoD/F, Rnd, 
RhoU/V, RhoH and RhoBTB – according to sequence and phylogenetic similarity 
(adapted from Aspenström et al., 2007). 
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Although GDP-GTP exchange reactions could occur 
spontaneously in the cell, the dissociation rate of bound GDP as well as 
the hydrolysis of GTP inherent to GTPases activity is extremely slow and 
poorly efficient, and therefore requires the specific regulatory proteins 
described in the following to catalyze the process. Additionally, these 
proteins participate in the spatial regulation of the activation/inactivation 
cycle (Takai et al., 2001; Vetter and Wittinghofer, 2001; Schmidt and Hall, 
2002; Bos et al., 2007). 
Guanine nucleotide exchange factors (GEFs) work as positive 
regulators of Rho GTPases activation. After a specific signal is relayed by 
cell receptors, GEFs are recruited to cellular membranes, where they bind 
small GTPases, enhance the release of bound GDP and promote its 
replacement by GTP, that is found in a much higher concentration in the 
cytosol than GDP. With the opposite role, GTPase-activating proteins 
(GAPs) bind to small GTPases and stimulate their intrinsic GTPase 
activity to hydrolyse the bound GTP and convert active Rho proteins into 
inactive GDP-bound forms (Fig. 2) (Van Aelst and D’Souza-Schorey, 
1997; Kaibuchi et al., 1999; Schmidt and Hall, 2002; Bos et al., 2007). An 
additional level of regulation is provided through guanine nucleotide 
dissociation inhibitors (GDIs) that were initially described as simple 
inhibitors of Rho GTPases activity but whose function is now recognized 
to be much more complex (Dovas and Couchman, 2005). GDIs can inhibit 
Rho GTPase activation in several ways. First, by intervening at the GDP-
GTP exchange step, preventing the dissociation of GDP and action of 
GEFs and therefore maintaining the protein in its inactive state. And 
second, by acting at the GTP hydrolytic step, blocking both the 
endogenous and GAP-catalyzed GTPase activity, impeding interactions 
with effectors. In addition, GDIs can modulate the distribution of Rho 
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GTPases between membranes and cytoplasm. This occurs by masking 
their prenyl modification and extracting inactive Rho proteins from cell 
membranes, producing soluble high-affinity complexes that keep them 
sequestered in the cytoplasm, away from their sites of activation at the 
membranes. In response to specific cues, the complex Rho GTPase-GDI 
is targeted to the plasma membrane where GDI is displaced and the 
GTPase can be activated again (reviewed in DerMardirossian and 
Bokoch, 2005; Dovas and Couchman, 2005; Garcia-Mata et al., 2011). In 
parallel with regulating Rho protein cycling, GDIs contribute also to the 
maintenance of a cytoplasmic pool of inactive Rho GTPases that, in 
response to a signal, can rapidly be translocated to a cell membrane to be 
activated (Fig. 2) (Van Aelst and D’Souza-Schorey, 1997; Kaibuchi et al., 
1999;  DerMardirossian and Bokoch, 2005; Garcia-Mata et al., 2011). 
  To date, a large number of Rho-GEFs (~70) and Rho-GAPs (~80) 
have been identified in the human genome and these have shown to be 
functionally redundant (Schmidt and Hall, 2002; Rossman et al., 2005; 
Bos et al., 2007; Heasman and Ridley, 2008). Indeed, multiple GEFs, 
GAPs and GDIs participate in the activation/inactivation cycle of the same 
Rho GTPase. This diversity of regulators and apparent redundancy 
pointed to cell-specific expression and specific receptor pathway-
dependency (Scita et al., 2000; Ellenbroek and Collard, 2007). Thus, the 
activation state of Rho proteins is tightly regulated and occurs in a cell-
type and pathway-dependent manner, depending upon the balance of the 
regulators (GEFs, GAPs and GDIs) at any given moment, and this 
determines its downstream signalling (Raptis et al., 2011).   
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Figure 2: The cycle of activation/inactivation of Rho GTPases. Following a 
specific extracellular stimulus, guanine nucleotide exchange factors (GEFs) 
catalyze the exchange of GDP for GTP, enabling the interaction of GTPases with 
specific effectors leading to cellular responses. In opposite, GTPase-activating 
proteins (GAPs) inactivate GTPases by stimulating their intrinsic GTPase activity. 
GDP-bound GTPases are maintained mainly cytoplasmic by guanine nucleotide 
dissociation inhibitors (GDIs) that masks the C-terminal tail required for plasma 
membrane localization. Upon dissociation of the GDI, GTPases translocate back 
to the plasma membrane, where they can be activated by GEFs (adapted from 
Ellenbroek and Collard, 2007). 
 
1.1.2. Biological functions 
 
Most of the functional information available on Rho-family proteins 
has come from studies on the best-characterized members RhoA, Rac1 
and Cdc42 (Bishop and Hall, 2000; Etienne-Manneville and Hall, 2002). 
These were first described for their distinct effects on the actin 
cytoskeleton. Experiments with quiescent Swiss 3T3 fibroblasts showed 
that the activation of RhoA induced the formation of stress fibres, 
elongated actin bundles that transverse the cells and promote cell 
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attachment to the extracellular matrix through focal adhesions. In turn, 
active Rac1 promoted the assembly of a meshwork of actin filaments at 
the cell periphery to produce lamellipodia and membrane ruffles. The 
activation of Cdc42 produced actin-rich, finger-like cytoplasmic extensions 
called filopodia, which are probably involved in the recognition of the 
extracellular environment (Hall, 1998). These highly specific effects on the 
actin cytoskeleton were observed in many other cell types, including 
epithelial and endothelial cells, astrocytes and lymphocytes (Hall, 1998; 
Etienne-Manneville and Hall, 2002), pointing to a series of well-defined 
signal transduction pathways controlled by each GTPase, leading to both 
the formation and the organization of actin filaments (Jaffe and Hall, 
2005).  
The control of actin cytoskeleton rearrangements allows Rho 
proteins to influence various cytoskeleton-dependent processes, such as 
cell migration, cytokinesis, morphogenesis, cell adhesion and polarity, 
tissue architecture, phagocytosis and axon guidance (Van Aelst and 
D’Souza-Schorey, 1997; Bishop and Hall, 2000; Etienne-Manneville and 
Hall, 2002). In addition to the strong role in actin dynamics regulation, Rho 
GTPases have been associated to a wide variety of biological functions 
(Bishop and Hall, 2000; Etienne-Manneville and Hall, 2002; Jaffe and Hall, 
2005).  
 The diversity and complexity of Rho functional properties is 
consistent with the large number of target proteins with which they bind 
and interact, exerting their effects. Each Rho-family protein has binding 
affinity for multiple effectors, some expressed in specific cellular context, 
and some effectors are recognized by multiple family members (Bishop 
and Hall, 2000; Etienne-Manneville and Hall, 2002). Until now, over 70 
effector proteins have been identified (Ellenbroek and Collard, 2007), 
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including protein kinases, lipid kinases, lipases, oxidases, phosphatases 
and scaffold proteins (Cotteret and Chernoff, 2002; Jaffe and Hall, 2005). 
Among these, protein kinases that act by phosphorylation of downstream 
target proteins, constitute an important group with some well-
characterized elements, like Rho-associated coiled-coil-containing protein 
kinases (ROCKs or RHO kinases) that bind to active RhoA and p21-
activated kinases (PAKs) that bind to active Rac1 and Cdc42 (Sahai and 
Marshall, 2002; Ellenbroek and Collard, 2007). Many of Rac1 and Cdc42 
effectors (e.g. PAK, Wiskott-Aldrich-syndrome protein – WASP) contain a 
conserved GTPase-binding consensus site, the Cdc42/Rac interactive 
binding domain (CRIB), to which the GTP-bound forms of Rac1 and 
Cdc42 bind specifically and together with additional binding regions 
contribute to a productive interaction. A characteristic binding region 
called amino (N-) terminal Rho effector homology domain (REM) is also 
found in some RhoA effectors, like rhotekin (RTKN) (Bishop and Hall, 
2000). The CRIB and REM binding domains derived from various 
downstream effectors have been exploited as very useful biochemical 
tools to study the activation of Rho GTPases (Aspenström et al., 2004). 
Much of our insight into the biological activities of individual Rho 
GTPases has come from overexpression studies in cell lines with 
dominant-negative and constitutively active mutants. Dominant-negative 
mutants were created through the substitution of the amino acid (aa) Thr 
for Asn (T17N for Rac1 or Cdc42 and T19N for RhoA). This point mutation 
allows binding of GEFs but inhibits downstream interactions with effector 
proteins, generating a non-productive complex that competes with 
endogenous proteins for binding to GEFs. Amino acid substitutions of Gly 
to Val or Gln to Leu  (G12V or Q61L for Rac1 or Cdc42 and G14V or 
Q63L for RhoA) produce constitutively active mutants, that signal 
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continuously to their effectors due to blockage of intrinsic and GAP-
promoted GTP hydrolysis. Although quite useful and informative, this 
approach lacks in specificity, since some GEFs and GAPs do not 
distinguish between the members of the Rho-family, so that these mutants 
can affect other GTPase pathways and thus results need to be interpreted 
with caution (Bishop and Hall, 2000; Heasman and Ridley, 2008; Spiering 
and Hodgson, 2011). More recently, other strategies such as RNA 
interference (RNAi) and gene knockout in mice have allowed selective 
inactivation of different Rho GTPases and their regulators and subsequent 
analysis of in vivo function, but they too have limitations, once again due 
to functional redundancy between closely related Rho proteins 
(Tybulewicz and Henderson, 2009; Hall and Lalli, 2010). 
  
1.1.3. Association with cancer	  
 
 Cancer can be generally seen as a disease involving dynamic 
changes in the genome. It is a complex, multi-step process that reflects 
the accumulation of acquired genetic and epigenetic alterations that result 
in alterations of key signalling pathways, and thus in the progressive 
transformation of normal cells into malignant derivatives (Gray and 
Collins, 2000; Hanahan and Weinberg, 2000; Cairns, 2009). According to 
Hanahan and Weinberg (2000), tumorigenesis requires six essential 
alterations to normal cell physiology: self-sufficiency in growth signals, 
insensitivity to anti-growth signals, evasion to apoptosis, unlimited 
replicative potential, sustained angiogenesis for nutrient supply, and ability 
to invade neighbouring tissues and metastasize.  
The discovery of activating mutations that converted proto-
oncogenes into oncogenes, conferring them with gain of function and thus 
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causing many of the perturbations in cell growth and differentiation seen in 
cancer cells, revolutionized cancer research and boosted it to search for 
more mutations (Hanahan and Weinberg, 2000; Cairns, 2009). In fact, 
Rho-family proteins were initially cloned on the basis of their similarity to 
the RAS oncogenes (Sahai and Marshall, 2002). RAS is one of the most 
important oncogenes in humans, mutated in about 30% of cancers of 
different origins (Hernández-Alcoceba et al., 2000), contributing to several 
aspects of the malignant phenotype, including the deregulation of tumour-
cell growth, programmed cell death and invasiveness, and the ability to 
induce new blood-vessel formation (Downward, 2003). However, to date, 
the hypothesis that Rho proteins could also present homologous 
activating mutations in their coding sequence has not been confirmed 
(Benitah et al., 2004; del Pulgar et al., 2005). Nevertheless, Rho GTPases 
were found to play in vitro an essential role in Ras-induced transformation 
(Boettner and Van Aelst, 2002; Sahai and Marshall, 2002; Karlsson et al., 
2009). This finding and all the cellular functions assigned to Rho GTPases 
with impact on tumour formation and progression, like the regulation of 
polarisation, migration, proliferation and survival of cells, strengthened the 
link between aberrant Rho signalling and cancer. Although recent whole 
exome sequencing efforts have revealed an oncogenic Rac1 mutation in 
codon 29 of 5-9% of melanoma cases (Hodis et al., 2012; Krauthammer et 
al., 2012), Rho signalling deregulation appears to be occurring at the level 
of GTPase expression or its activation by mutation in their upstream 
regulators or downstream effectors (Ellenbroek and Collard, 2007).    
 In fact, it has been reported that Rho proteins expression or 
activity is frequently altered in human cancers or cancer-derived cell lines 
(Ellenbroek and Collard, 2007; Vega and Ridley, 2008). For example, 
overexpression of RhoA has been observed in breast, colon, lung (Fritz et 
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al., 1999), and gastric cancer, as well as in head and neck squamous cell 
carcinoma (HNSCC), bladder and testicular cancer (Ellenbroek and 
Collard, 2007). Studies that compared malignant breast tissue with benign 
tissue showed that Rac1 protein levels were elevated in malignant breast 
tissue, suggesting that increased Rac activity promotes breast cancer 
development (Fritz et al., 1999). Also, the highly active splice variant of 
Rac1, Rac1b, was found overexpressed in some tumour types (Jordan et 
al., 1999; Schnelzer et al., 2000). Altered expression of Rho GTPases can 
take place at the messenger RNA (mRNA) level or at the protein level and 
have been linked to prognosis and development of diseases (Benitah et 
al., 2004; del Pulgar et al., 2005; Ellenbroek and Collard, 2007). 
In addition to aberrant expression of Rho GTPases, also altered 
expression and mutations of regulatory proteins (GEFs, GAPs and GDIs), 
as well of effector proteins (e.g. ROCK; PAK) have been described for 
various human tumours (del Pulgar et al., 2005; Ellenbroek and Collard, 
2007; Vega and Ridley, 2008). It is not clear how the altered expression of 
these various proteins influences Rho GTPase activity in cancer and 
indeed whether the connection between these upregulated proteins and 
the associated Rho GTPases is relevant for tumour progression (Vega 
and Ridley, 2008).  
Nowadays, the literature reports contributions of Rho proteins to 
most steps of cancer initiation and progression. Although best 
characterized for their effects on the cytoskeleton and cell adhesion and 
these implied most likely an effect in cell migration and invasion, the 
function of Rho GTPases is not restricted to these events and they can 
affect tumour cells through regulation of gene expression, cell growth and 
survival, intracellular transport of signalling molecules or modifying the 
interaction of cancer cells with surrounding stromal cells (Sahai and 
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Marshall, 2002; Ridley, 2004; Ellenbroek and Collard, 2007; Vega and 
Ridley, 2008).  
The initiation of tumour formation reflects the coordination of 
uncontrolled proliferation and the evasion of apoptosis (Ridley, 2004; 
Ellenbroek and Collard, 2007). Rho proteins contribute to cell survival by 
either promoting or antagonizing apoptosis in a cell type-specific manner 
(Sahai and Marshall, 2002; Karlsson et al., 2009). The increased 
production of superoxides and subsequent activation of nuclear factor 
kappa-light-chain-gene-enhancer of activated B cells (NF-κB) is one of the 
mechanism by which cells are protected from apoptosis, however a 
mechanism that involves phosphorylation of the apoptotic regulator BCL-2 
antagonist of cell death (BAD) by PAK has also been proposed (Sahai 
and Marshall, 2002).  
 Cell cycle progression is tightly regulated and follows an ordered 
progression of molecular events, involving the activation of cell cycle 
regulatory molecules, including cyclins, cyclin-dependent kinases (CDKs) 
and CDK inhibitors (CKIs) (Matsumura et al., 1999). Genetic analysis of 
human tumours has revealed that some of the molecules most often 
altered in cancer are those involved in the control of the G1/S transition of 
the cell cycle, a time when cells become committed to a new round of cell 
division.  One of the primary events in the early G1 phase, dependent of 
extracellular mitogenic signals, is the synthesis of D-type cyclins (mainly 
cyclin D1) (Ortega et al., 2002). D-type cyclins family is composed of three 
closely related proteins, cyclin D1, D2 and D3, expressed in a wide variety 
of organs in a tissue-specific manner (Friedrichsen et al., 2003). These 
cyclins associate with CDK4 or 6, which up-regulates the kinase catalytic 
activity, and leads to the phosphorylation and partial inactivation of the key 
substrate retinoblastoma protein (Rb). Consequently, members of 
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transcription factor E2F family are released from growth-inhibitory Rb 
complexes and activated, leading to transcription of genes important for S-
phase activity, such as cyclin E. Next, cyclin E interacts with and activates 
CDK2 kinase, leading to hyperphosphorylation of Rb proteins, which is 
required for proper G1/S transition and S-phase entry. The G1/S transition 
is also negatively regulated by CKIs that bind to cyclin-CDK complexes 
and inhibit their activity. Based on their sequence homology and specificity 
of action, CKIs are divided into two families: INK4 and Cip/Kip. Members 
of the INK4 family of CKIs, namely p16INK4a (CDKN2A), p15INK4b 
(CDKN2B), p18INK4c (CDKN2C), and p19INK4d (CDKN2D), specifically inhibit 
the activity of CDK4 and CDK6 by preventing cyclinD binding. On the 
other hand, the Cip/Kip family members, that include p21CIP1/WAF1 
(CDKN1A), p27KIP1 (CDKN1B), and p57KIP2 (CDKN1C), act more broadly 
and inhibit the activity of preformed cyclin–CDK complexes (reviewed in 
Obaya and Sedivy, 2002; Ortega et al., 2002).  
 Genetic alterations or abnormal expression of numerous cell cycle 
components have been implicated in tumorigenic processes. In particular, 
given the critical role and the potential to disrupt the cell cycle, cyclin D1 
and CKIs have been assigned as oncogenes and tumour suppressors, 
respectively (Obaya and Sedivy, 2002; Mermelshtein et al., 2005). 
Multiple pathways seem to link Rho proteins to the control of cyclin D1 
levels. Many of these involve the activation of protein kinases, leading to 
the subsequent modulation of transcription factor activity. Cyclin D1 
transcription is controlled by ETS, activator protein 1 (AP-1) and NF-κB 
transcription factors (Albanese et al., 1995; Shaulian and Karin, 2001; 
Hinz et al., 2002), the activity of which is regulated by RhoA, Rac1 and 
Cdc42 (Perona et al., 1997; Sahai and Marshall, 2002). Rho GTPases can 
also regulate the activities of CKIs. RhoA signalling modulates the levels 
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of p21CIP1/WAF1 and p27KIP1. Downregulation of p21CIP1/WAF1 levels by active 
RhoA is crucial for oncogenic RAS to promote cell-cycle entry (Olson et 
al., 1998). Inhibition of p27KIP1 seems to require RhoA activity, but it is not 
clear whether this is a direct effect or achieved through effects on cyclin E-
CDK complexes, which can promote p27KIP1 degradation (Sahai and 
Marshall, 2002; Coleman et al., 2004).  
 
1.2. Rac1 
  
 The GTPase Rac1 is probably the founder member of the Rho 
family (Boureux et al., 2007). Initially discovered as Ras-related C3 
botulinum toxin substrate 1 (Didsbury et al., 1989) is nowadays 
considered to be a canonical member of Rho-family and one of the most 
studied (Bishop and Hall, 2000; Etienne-Manneville and Hall, 2002; Bosco 
et al., 2009). Together, Rac1 with its splice variant Rac1b, Rac2, Rac3 
and RhoG comprise the Rac subfamily of Rho GTPases, sharing 
significant sequence identity (more than 80% between the Rac isoforms) 
and diverging essentially in the C-terminal region (Wennerberg and Der, 
2004). 
 Rac1 is ubiquitously expressed (Didsbury et al., 1989) and its 
promoter presents characteristics similar to a housekeeping gene: a small 
size, the lack of a TATA-box and a CCAAT-box, an high GC content 
(74,2%), a CpG island surrounding the transcription initiation sites, and a  
number of known consensus sequences for transcription factors, such as 
Sp1, c-Jun/c-Fos (AP-1, AP-2, AP-4), E2F-2, Ikaros2, MZF1 and the 
oncogene ETS1 (Matos et al., 2000). Rac1 is encoded by the RAC1 gene, 
whose deletion results in early embryonic lethality (Sugihara et al., 1998), 
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evidencing the critical role of the signalling pathways in which this GTPase 
is involved.  
 Indeed, beyond the first insights into Rac1 cellular function as a 
regulator of actin cytoskeleton reorganization, it has been implicated in a 
myriad of processes that go from cell proliferation, apoptosis, motility, 
membrane trafficking and superoxide production to transcriptional 
regulation (Jaffe and Hall, 2005). These functions are mediated through 
interaction with specific effectors. One such effector, for example, is the 
protein kinase PAK that becomes activated upon direct interaction with 
GTP-Rac1. Activated Rac1 also stimulates transcription factors and gene 
expression, for example following its activation of the c-Jun N-terminal 
kinase (JNK) cascade (Coso et al., 1995), or of the transcription factor NF-
κB (Perona et al., 1997). The pathway that links Rac1 to NF-κB involves 
the production of reactive oxygen species (ROS) and occurs in epithelial 
cells via NOX1 during Rac1-induced mitogenesis (Sulciner et al., 1996; 
Joneson and Bar-Sagi, 1998; Park et al., 2004). Rac1-stimulated ROS 
formation activates NF-κB leading to increased cyclin D1 expression and 
subsequent cell cycle progression (Guttridge et al., 1999; Hinz et al., 
1999; Joyce et al., 1999), independent of the extracellular signal-regulated 
kinase (ERK) or JNK kinase cascade (Lamarche et al., 1996). 
 
1.2.1. The efector PAK 
 
Among the first described and best-characterized effectors of Rac1 
are the PAK kinases (Manser et al., 1994).    
PAKs are a highly conserved group of serine/threonine kinases 
represented, in mammals, by six isoforms (PAK1 to PAK6) subdivided into 
two groups according with their biochemical and structural features.  
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Group I is constituted by PAK1 (αPAK), PAK2 (γPAK) and PAK3 (βPAK), 
whereas PAK4, PAK5 and PAK6 belong to group II (Jaffer and Chernoff, 
2002; Bokoch, 2003).  
The group I PAKs, on which we will focus, comprise an N-terminal 
regulatory domain and a highly conserved C-terminal catalytic domain.  
The regulatory domain includes a conserved p21-binding domain (PBD), 
partially overlapped by an autoinhibitory domain (AID), crucial for 
controlling basal kinase activity. The PBD is responsible for the overall 
binding of the active forms of Rac1/Cdc42 (the CRIB – Cdc42/Rac1-
interactive binding – domain [aa 75-90 in PAK1] is included in this region 
and contributes for the binding). Structural and biochemical data has 
shown that PAKs exists in cells as homodimers in a trans-autoinibitory 
conformation, in which the AID of one molecule inhibits the catalytic 
domain of the other (Fig. 3) (Jaffer and Chernoff, 2002; Bokoch, 2003).  
The activation mechanism of PAKs can be GTPase-dependent or 
independent, although the molecular mechanisms underlying this last 
have not been clear yet. In a GTPase-dependent activation mechanism, 
the binding of active Rac1 or Cdc42 to the PBD disrupts PAK dimerization 
and releases the inhibition, allowing autophosphorylation of the threonine 
residue (T423 for PAK1) in the activation loop of the catalytic domain. 
Phosphorylation of this site activates PAK and is important for maintaining 
relief from autoinhibition, even in the absence of the GTPase, and for full 
kinase activity (Fig. 3). An acidic substitution of this residue (T423E for 
PAK1) renders PAK constitutively active. Activated PAKs can 
phosphorylate multiple substrates or interact with other proteins and 
through them modulate a range of biological activities, including the 
regulation of cytoskeletal dynamics and cell motility, stimulation of cell 
proliferation, pro- and anti-apoptotic signals and regulation of gene 
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expression (reviewed in Jaffer and Chernoff, 2002; Bokoch, 2003; 
Dummler et al., 2009). Deregulation of these cellular processes can 
promote tumorigenesis and in fact, overexpression and/or hyperactivation 
of PAK family members, have been detected in several human tumours. 
In breast cancer, for example, deregulation of PAK1 is well documented 
and correlates with increased invasiveness and survival of these cancer 
cells (Kumar et al., 2006). PAK1 expression was also found increased 
during malignant progression on human colorectal cancer (Gururaj et al., 
2005).                
 
Figure 3: Domain structure and activation mechanism of group I PAKs. The 
group I Paks contain a N-terminal regulatory domain and a C-terminal catalytic 
domain. The regulatory domain includes a conserved p21-binding domain (PBD), 
partially overlapped by an autoinhibitory domain (AID), crucial for controlling basal 
kinase activity. PAKs are maintained in an inactive, autoinhibited dimeric 
complex, in which the AID of one molecule inhibits the catalytic domain of the 
other. The binding of an active form of Rac1 to the PBD disrupts PAK 
dimerization and releases the inhibition, allowing autophosphorylation and 
activation of the kinase (adapted from Parrini et al., 2005).  
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1.2.2. Rac1b 
  
 Recently, it was found that the RAC1 gene encoded a second 
isoform, designated Rac1b, through an alternative splicing event. Rac1b 
transcripts can be amplified from a variety of normal epithelial tissues, with 
a stronger prevalence in colon-derived samples, but is normally less 
abundant that the Rac1 transcripts (Jordan et al., 1999). Curiously, Rac1b 
was found overexpressed in colorectal (Jordan et al., 1999), breast 
(Schnelzer et al., 2000) and lung tumours (Liu et al., 2012; Stallings-Mann 
et al., 2012; Zhou et al., 2012) both at the RNA and protein levels, when 
compared to levels in benign tissue. This result was very interesting and 
suggested a role of Rac1b in tumorigenesis. 
The GTPase Rac1b is the result of the inclusion of an additional 
exon 3b, located between exons 3 and 4 of RAC1 gene, into the Rac1 
mRNA. Thus, Rac1b transcript contains an additional 57 nucleotides (nt) 
that encodes an in frame insertion of 19 amino acids between Rac1 
residues 75 and 76, positioned immediately C-terminal to the Switch II 
domain (Jordan et al., 1999). As already stated, the Switch II domain 
(Rac1 residues 60–76) along with the Switch I domain (Rac1 residues 30–
38), constitute the regions that change in conformation during GDP-GTP 
cycling and consequently, contribute for interaction with regulators and 
effectors (Vetter and Wittinghofer, 2001; Wennerberg et al., 2005).  
Rac1b was shown to be a highly activated variant. The analysis of 
the total endogenous level of Rac1b protein versus the activated GTP-
bound fraction revealed that, although present in small amounts in cells, 
the amount of active Rac1b is surprisingly high, and even can exceed the 
amount of active Rac1 (Matos et al., 2003).  
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The high activation level of Rac1b is due to several differences. 
Rac1b is unable to interact with Rho-GDI and consequently to cycle 
between the plasma membrane and the cytoplasm, which leaves it 
persistently associated with membranes, in a favoured position to become 
activated (Matos et al., 2003). Additionally, Rac1b shows impaired intrinsic 
GTPase activity in vitro (Schnelzer et al., 2000), yet maintaining GAP 
responsiveness in vivo (Matos et al., 2003) and in vitro (Fiegen et al., 
2004; Singh et al., 2004). And it also reveals an increased intrinsic 
nucleotide exchange rate (GDP to GTP) in vitro (Schnelzer et al., 2000). 
Curiously, however, Rac1b failed to activate several classical Rac1 
pathways, as the formation of lamellipodia, the activation of the protein 
kinase PAK, or the stimulation of JNK pathway. Because Rac1b retained 
the ability to stimulate the classical NF-κB pathway it seems to be 
selective in its downstream signalling properties (Matos et al., 2003).  
 
1.3. Gene expression regulation 
 
 For all living cells the accurate execution of biological processes 
such as development, homeostasis, differentiation or adaptation to the 
environment requires a precise and coordinated set of steps that depend 
on the proper spatial and temporal expression of genes. Thus, 
deregulation of gene expression is often linked with the occurrence of 
diseases (Emerson, 2002; Maston et al., 2006). Cancer, for example, is 
essentially a disease of disordered gene expression, driven by the 
accumulation of genetic and epigenetic alterations that gradually 
transform normal cells into cancer cells (Gray and Collins, 2000; Hanahan 
and Weinberg, 2000).  
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 Eukaryotic gene expression is a highly complex and dynamic 
process that involves several steps, including transcription of the gene, 
mRNA processing (e.g. splicing, polyadenylation), transport of the fully 
processed mRNA to the cytoplasm, translation into a protein and post-
translational modifications that confer the protein its mature form (Singer 
and Green, 1997; Maston et al., 2006). Gene expression can be 
specifically regulated at any point of the process, however, the critical step 
seems to be at the level of transcription initiation (Maston et al., 2006; 
Hager et al., 2009).  
 
1.3.1. Eukaryotic gene transcription 
 
 Transcription is, in a simple definition, the biochemical process by 
which information is transferred from DNA to RNA. However, this process 
it is all but simple, involving distinct stages – initiation, elongation and 
termination – and a large number of regulatory proteins (Venters and 
Pugh, 2009).  
 Transcription initiation is triggered by the binding of transcription 
factors to specific DNA sequences located in cis-regulatory elements, 
such as gene promoters or enhancers. In turn, transcription factors 
activation is controlled by many signal transduction pathways, which 
respond to distinct cellular and environmental signals (Orphanides and 
Reinberg, 2002; Bilu and Barkai, 2005; Venters and Pugh, 2009). The 
significance of this regulatory process is even more highlighted by the fact 
that about 10% of the human gene products are predicted to have DNA-
binding properties (Kim and Park, 2011). Therefore, extracellular signals 
are believed to constitute the main regulatory source for transcriptional 
regulation. 
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 In eukaryotes, this process is carried out by three different      
DNA-dependent RNA polymerases: RNA polymerase (Pol) I, II and III. 
RNA Pol I synthesises ribosomal RNA (rRNA) and RNA Pol III produces 
transfer RNAs (tRNA) and some small RNAs, while RNA Pol II is 
responsible for transcribing protein-coding genes into mRNAs and 
producing small nuclear RNA genes (snRNA) (Cramer et al., 2008). 
 In case of RNA Pol II, the factors involved in the transcription of 
genes can be classified into three groups: general transcription factors 
(GTFs), promoter-specific activator or repressor proteins, and co-
activators or co-repressors. GTFs, in contrast to sequence-specific 
regulators that are targeted to a discrete set of genes, are broadly utilized 
by the cell at many genes and can be sufficient for accurate transcription 
initiation in vitro. GTFs are constituted by RNA Pol II and a variety of 
auxiliary components, including TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and 
TFIIH. Additionally to these factors it is required a highly conserved, large 
multisubunit complex, the Mediator. GTFs assemble on the core promoter 
in an ordered manner to form a transcription preinitiation complex (PIC), 
which directs RNA polymerase II to the transcription start site (TSS). The 
first step in PIC assembly is binding of TFIID, a multisubunit complex 
consisting of TATA-box-binding protein (TBP) and a set of tightly bound 
TBP-associated factors (TAFs). Transcription then proceeds through a 
series of steps, including promoter melting, clearance, and escape, before 
a fully functional RNA Pol II elongation complex is formed (Lemon and 
Tijan, 2000; Maston et al., 2006; Venters and Pugh, 2009).  
 The assembly of a PIC on the core promoter is sufficient to direct 
only low levels of accurately initiated transcription from DNA templates in 
vitro, a process generally referred to as basal transcription. Transcriptional 
activity is further regulated by a second class of factors, termed activators 
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or repressors. In general, these transcription factors are sequence-specific 
DNA-binding proteins whose recognition sites are usually present in 
sequences upstream of the core promoter. Many activators and 
repressors interact with other proteins known as respectively, co-
activators or co-repressors, that do not have DNA-binding activity but help 
the transcription factor to execute its function (Gaston and Jayaraman, 
2003; Maston et al., 2006).  
 Both activators and co-activators can further stimulate transcription 
by promoting the alteration of chromatin structure in the vicinity of the 
promoter. Three classes of protein associated with the RNA Pol II are 
involved in this remodelling of chromatin: histone-modifying enzymes, 
chromatin-binding proteins, and ATP-dependent nucleosome-remodelling 
proteins. Activators and co-activators can recruit one or more of these 
proteins to a promoter and the resulting chromatin remodelling can alter 
histone-DNA interactions, nucleosome-nucleosome interactions, and/or 
re-position nucleosomes relative to transcription factor binding sites 
(Lemon and Tijan, 2000; Gaston and Jayaraman, 2003; Venters and 
Pugh, 2009). 
 Transcriptional repression is of two types: general or global 
repression and gene-specific repression. General repression occurs when 
a repressor protein or complex either sequesters or modifies a central 
component of the PIC or a component of RNA Pol II, so that it is 
unavailable for transcription. Thus, general repression will downregulate 
the expression of all the genes transcribed by RNA Pol II. In contrast, 
gene-specific repression involves the sequence-specific binding of a 
repressor protein to the promoter region of specific target genes (reviewed 
in Gaston and Jayaraman, 2003; Payankaulam et al., 2010). 
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1.3.2. Transcriptional regulatory elements 
 
 A typical eukaryotic protein-coding gene comprises two distinct 
families of cis-acting regulatory elements: the promoter and distal 
regulatory elements (Butler and Kadonaga, 2002; Levine and Tjian, 2003). 
These cis-regulatory elements contain a series of short DNA sequence 
motifs (between 6 and 20 bp) that are specifically recognized and bound 
by transcription factors to either increase or decrease transcription of gene 
targets (Maston et al., 2006; Georges et al., 2010).  
 Promoters are divided into core and proximal promoters depending 
on their binding partners and distance from the TSS (Fig. 4) (Kim and 
Park, 2011). The core promoter encompasses the TSS (defined as +1) 
and flanking sequences extending about ~35 bp in each direction, to 
which RNA Pol II and the general transcriptional machinery bind to initiate 
and direct transcription. In higher eukaryotes, this region is highly diverse 
and can include multiple regulatory elements that interact with various 
components of the basal transcriptional machinery, such as the TATA 
box, the initiator element (Inr), the downstream promoter element (DPE), 
the downstream core element (DCE), the TFIIB-Recognition Element 
(BRE) and the motif ten element (MTE) (reviewed in Butler and 
Kadonaga, 2002; Smale and Kadonaga, 2003; Maston et al., 2006). The 
most familiar core promoter element is the TATA box, an A/T rich 
sequence, usually located at approximately 25 to 30 nt upstream of the 
TSS. Its consensus sequence, TATA(A/T)A(A/T)(A/G), is recognized by 
TBP, a subunit of the TFIID complex, constituting the first step in PIC 
assembly (reviewed in Smale and Kadonaga, 2003). Although an 
important nucleation point, PIC assembly and ultimately, transcription 
initiation does not depend on TATA box (which is absent from many 
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promoters) or on any single element. In fact, with the exception of the 
BRE, which is specifically recognized by TFIIB, all the other core promoter 
elements are TFIID-interaction sites and stabilize PIC assembly. The 
variability in content and organization shown by core promoters 
contributes to the regulatory specificity of genes (Maston et al., 2006). 
 The proximal promoter is defined as the region immediately 
upstream from the core promoter (within <1 kb) that contains DNA 
sequences (e.g. CCAAT box, octamer module and GC-box) recognized by 
specific transcription factors (Maston et al., 2006; Kim and Park, 2011). 
The interaction between these regulatory DNA elements and transcription 
factors stimulates transcription by stabilizing the binding of general 
transcription factors to nearby core promoters (Kim and Park, 2011). 
These factors do not always function as classical activators or repressors, 
instead, they might serve as tethering elements that recruit distal 
enhancers to the core promoter (Levine and Tjian, 2003). 
 Distal regulatory elements are often located far away from the 
genes they control, scattered over distances of more than 100 kb from the 
TSS, either upstream of the promoter, in a intron or even at the 3´ end of a 
gene (Levine and Tjian, 2003; Maston et al., 2006). These long-range 
regulatory elements are essential in mediating the complex patterns of 
gene expression in different cells types (Levine and Tjian, 2003; 
Heintzman and Ren, 2009). Examples of some of these regulatory 
elements include enhancers, silencers, insulators and locus control 
regions (LCR) (reviewed in Noonan and McCallion, 2010). 
 Enhancers are typically composed of clusters of DNA-binding sites 
for transcriptional regulators that work cooperatively to enhance 
transcription, independent of their orientation and distance from the 
promoter. The spatial organization and orientation of the transcription 
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binding sites within an enhancer can be critical to its regulatory activity. 
Silencers are sequence-specific elements that confer a negative, (i.e., 
silencing or repressing) effect on the transcription of a target gene (Fig. 4) 
(Lee and Young, 2000; Maston et al., 2006). 
 
 
Figure 5: Schematic representation of cis-regulatory elements. The core 
promoters directly upstream of transcription start site (TSS) bind the general 
transcriptional machinery. Proximal promoters bind cognate sequence-specific 
transcription factors (shown as trapezoids). Distal enhancers and silencer 
elements also provide binding sites for sequence-specific transcription factors, but 
have opposite regulatory effects on the transcription activity of regulated genes 
(adapted from Kim and Park, 2011). 
 
1.3.3. The role of chromatin 
 
 Chromatin is the state in which DNA is packaged within the cell. 
The nucleosome is the fundamental unit of chromatin and it is composed 
of an octamer of the four core histones (H3, H4, H2A, H2B) around which 
147 base pairs of DNA are wrapped. The core histones are predominantly 
globular except for their N-terminal tails, which are unstructured. A striking 
feature of histones, and particularly of their tails, is the large number and 
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type of modified residues they possess (Kouzarides, 2007; Clapier and 
Cairns, 2009). 
 Both histone tails and globular domains are subject to a vast array 
of post-translational modifications. These modifications include 
methylation of arginine (R) residues, methylation, acetylation, 
ubiquitination, ADP-ribosylation, sumoylation of lysines (K) and 
phosphorylation of serines and threonines. Modifications that are 
associated with active transcription, such as acetylation of H3 and H4 or 
di- or trimethylation of H3 K4, are commonly referred to as euchromatin 
modifications. Modifications that are localized to inactive genes or regions, 
such as H3 K9me and H3 K27me, are often termed heterochromatin 
modifications (Li et al., 2007). 
 Modifications may affect higher-order chromatin structure by 
affecting the contact between different histones in adjacent nucleosomes 
or the interaction of histones with DNA. Of all the known modifications, 
acetylation has the most potential to unfold chromatin since it neutralizes 
the basic charge of the lysine (Kouzarides, 2007). Typically, histone 
acetylation occurs at multiple lysine residues and is usually carried out by 
a variety of histone acetyltransferase (HAT) complexes. Distinct patterns 
of lysine acetylation on histones have been proposed to specify distinct 
downstream functions such as the regulation of co-expressed genes (Li et 
al., 2007).  
 
1.3.4. Transcription factors 
 
 Transcription factors are modular proteins consisting of a number 
of domains. The three major domains are a DNA-binding domain (DBD), a 
transactivation domain (TAD), and a dimerization domain (Kim and Park, 
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2011). In addition, transcription factors typically have a nuclear localization 
sequence (NLS), and some also have a nuclear export sequence (NES).  
  The DBD recognizes a specific DNA sequence and positions the 
transcription factor to the DNA. Transcription factors are typically grouped 
into families based on the similarities of the DBD structure. Such 
transcription factor families share a common motif, which is defined as a 
cluster of amino acid residues that has a characteristic three-dimensional 
folding pattern and carries out a specific function (Georges et al., 2010; 
Pan et al., 2010). As a consequence, it is common that many transcription 
factors within a family recognize either the same, or very similar, 
consensus DNA target sequences (Georges et al., 2010). Some of the 
more common and well described families include those containing a 
basic leucine zipper (bZIP), helix-loop-helix (HLH), Pit-Oct-Unc (POU), 
poxvirus and zinc finger (POZ), ETS or a forkhead DBD (Kelly and Daniel, 
2006; Georges et al., 2010). 
 The TAD is necessary for stimulating the activity of the 
transcription factor and the dimerization domain for the formation of 
homodimers or heterodimers (Maston et al., 2006). 
 
1.3.4.1. Signal transducers and activators of transcription (STATs) 
 
STATs are a family of latent cytoplasmic proteins that function as 
signalling transducers between the plasma membrane and the nucleus, 
and as transcription factors, activating a diverse set of genes (Darnell, 
1997; Yu and Jove, 2004). These proteins are activated by a series of 
extracellular signalling ligands, such as cytokines, growth factors, and 
hormones (e.g growth hormone – GH, prolactin – PRL), and therefore 
integrate diverse signalling pathways, controlling crucial biological 
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processes. Some of these include cell differentiation, proliferation, 
apoptosis, angiogenesis and immune responses (Horvath, 2000; Levy and 
Darnell, 2002).  
The general model of activation of STAT proteins relies on tyrosine 
phosphorylation events carried out by tyrosine kinases (TKs), like Janus 
kinase (JAK) proteins (JAK-STAT signalling pathway), receptor TKs or 
non-receptor TKs (e.g. SRC, ABL). Signalling initiates with binding of 
ligands to specific cell-surface receptors, which leads to receptor 
dimerization and to the activation of associated-TKs 
(transphosphorylation). These subsequently phosphorylate the receptor 
on tyrosine residues, providing docking sites for STATs recruitment. Once 
bound to the receptor complex, STATs are phosphorylated on specific 
tyrosine residues by the TKs, dimerize (homo or heterodimers) and 
translocate to the nucleus, where they bind to a consensus site (TTN5AA) 
in the promoter of target genes and activate transcription (Bowman et al., 
2000; Levy and Darnell, 2002; Alvarez and Frank, 2004).                    
 In mammals, the STAT family comprises seven members – 
STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6 – 
(Darnell, 1997) with a very similar functional domain structure and limited 
sequence homology, with exception of the STAT5 isoforms (Buitenhuis et 
al., 2004). All STAT proteins contain an N-terminal domain (mediates 
dimer-dimer interactions), a coiled-coil domain (important in interactions 
with other proteins), a highly conserved DBD, a Src-homology 2 (SH2) 
domain, a linker domain (bridges DBD and SH2 domain) and a C-terminal 
region that contains a TAD, as well as the critical tyrosine residue. The 
DBD is necessary for direct contact with specific DNA and its sequence 
determines the binding specificity for each STAT. The SH2 domain 
(common structural motif among signalling molecules) mediates protein-
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protein interactions through direct binding to specific phosphotyrosines, 
thereby is required for the recruitment of STATs to phosphorylated 
receptors and for the reciprocal SH2-phosphotyrosine interactions 
between monomeric STATs to form dimers. The most divergent region 
between STATs, and thus confering specificity, is the TAD that is essential 
for transcriptional activation. It also contains the tyrosine residue (e.g. 
Tyr694 for STAT5A) crucial for STAT activation and consequent, 
dimerization and nuclear translocation. With exception of STAT2 and 
STAT6, all STATs have in the TAD a conserved serine residue, whose 
phosphorylation further regulates STATs activity and contributes to 
maximal transcriptional activity (reviewed in Calò et al., 2003; Paukku and 
Silvennoinen, 2004; Santos and Costa-Pereira, 2011).  
 The STAT5 isoforms, STAT5A and STAT5B proteins, which are 
encoded by two distinct but closely related genes located in tandem on 
human chromosome 17, share over 90% of sequence identity with some 
differences at their TAD. Both proteins are widely expressed, but exhibit 
different expression profiles. These proteins share most of their biological 
functions, but display also non-redundant functions in vivo (Buitenhuis et 
al., 2004).   
 
1.3.4.2. BCL-6 
 
 BCL-6 was cloned from a translocation in diffuse large B-cell 
lymphoma (DLBCL). It is expressed in normal germinal centre (GC)        
B-cells and a subset of GC T-cells and has an essential role in normal 
antibody responses (Wagner et al., 2011). These alterations cause the 
deregulated expression of the BCL-6 gene by a mechanism called 
promoter substitution, that is the juxtaposition of heterologous promoters, 
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derived from other chromosomes, to the BCL-6 coding domain (Chang et 
al., 1996).  
 BCL-6 belongs to a subset of transcription factors which all have a 
similar structure composed of an N-terminal POZ domain and several zinc 
finger modules at the C-terminus (Dent et al., 2002). Its N-terminal POZ 
domain is able to recruit co-repressor molecules and histone deacetylase 
and thereby mediate transcriptional repression (Chang et al., 1996). An 
additional property is that the DNA-binding sequence recognized by   
BCL-6 conforms to the STAT family consensus-binding sequence (Dent et 
al., 1997), and BCL-6 has subsequently been shown to bind with varying 
affinities to different STAT sites (Harris et al., 1999). Thus an additional 
mechanism of action of BCL-6 might be the modulation of the effects of 
STATs by competing with differing affinities to different STAT target 
sequences. Such a role may be particularly important in situations in 
which STATs are responsible for driving conflicting biological processes, 
for example proliferation and differentiation (Logarajah et al., 2003). 
 
1.4. Objectives 
 
 The work described in this thesis had the following objectives: 
 
- Determine the effect of Rac1 signalling on gene expression 
regulation through the transcriptional repressor BCL-6;  
- Characterize whether gene transcription can be modulated by a 
STAT5/BCL-6 antagonism in colorectal cells;  
- Characterize the role of Rac1 signalling in the regulation of STAT5 
and BCL-6 responsive target genes.  
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2.1. Summary 
 
 Rac1 is a member of the Rho family of small GTPases that 
regulates signalling pathways involved in cell adhesion and migration but 
also the regulation of gene transcription. Here we describe that the 
transcriptional repressor BCL-6 is regulated by Rac1 signalling. 
Transfection of active Rac1 mutants into colorectal DLD-1 cells led to 
increased expression of a BCL-6-controlled luciferase reporter construct. 
Conversely, inhibition of endogenous Rac1 activation by the Rac1 inhibitor 
NSC23766 decreased reporter activity. Moreover, BCL-6 lost its typical 
localization to nuclear dots upon activation of Rac1 and became 
predominantly soluble in a non-chromatin bound cell fraction. Rac1 
signalling also regulated the expression of endogenous BCL-6-regulated 
genes, including the p50 precursor NFKB1/p105 and the cell adhesion 
molecule CD44. Interestingly, these effects were not stimulated by the 
alternative splice variant Rac1b. The mechanism of BCL-6 inhibition does 
not involve formation of a stable Rac1/BCL-6 complex and is independent 
of Rac-induced ROS production or JNK activation. We show that PAK1 
mediates the inhibition downstream of Rac and can directly phosphorylate 
BCL-6. Together, these data provide substantial evidence that Rac1 
signalling inhibits the transcriptional repressor BCL-6 in colorectal cells 
and reveal a novel pathway that links Rac1 signalling to the regulation of 
gene transcription. 
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2.2. Introduction 
  
 The Rho family of small GTPases contains 20 different gene 
members (Wherlock and Mellor, 2002; Boureux et al., 2007), of which 
RhoA, Rac1 and Cdc42 have been best characterized (Hall, 1998; Ridley, 
2001; Etienne-Manneville and Hall, 2002). These GTPases typically cycle 
between an inactive, GDP-bound, and an active, GTP-bound state. The 
transition between these states is controlled by three distinct types of 
proteins in vivo, the guanine nucleotide exchange factors (GEFs), which 
activate; and the GTPase-activating proteins (GAPs) or the guanine 
nucleotide dissociation inhibitors (GDIs), which both inactivate GTPases 
(reviewed in DerMardirossian and Bokoch, 2005; Bos et al., 2007). Once 
in the GTP-loaded conformation, Rho GTPases become able to interact 
with downstream effector proteins that initiate further signalling events in 
the cell. The corresponding cellular responses range from changes in cell 
morphology to changes in gene expression. 
Rac1, in particular, has been documented to stimulate the 
polymerization of actin filaments leading to the formation of lamellipodia 
and affecting the stability of adherens junctions (Fukata and Kaibuchi, 
2001). Rac signalling further activates the protein kinase PAK, the c-Jun 
N-terminal kinase (JNK) and the production of reactive oxygen species 
(ROS) (Schuringa et al., 2001). Moreover, recent data have revealed that 
Rac1 has also distinct roles in the regulation of gene transcription (Benitah 
et al., 2004). For instance, the stimulation of JNK by Rac signalling can 
lead to the activation of its target transcription factors c-Jun, ATF, ELK or 
AP-1. Also, Rac signalling can activate proteins of the STAT family 
(Schuringa et al., 2001; Park et al., 2004), and the formation of protein 
complexes between Rac1 and STAT3 or STAT5 were described (Simon 
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et al., 2000; Tonozuka et al., 2004; Kawashima et al., 2006). Likewise, an 
active Rac1 mutant amplifies the transcriptional activation mediated by    
β-catenin and TCF/LEF (Esufali and Bapat, 2004).  
A further important transcription factor stimulated by Rac1 is      
NF-κB. The NF-κB family is composed of five transcription factors that 
form homodimers or heterodimers with each other, namely RelA, RelB,   
c-Rel, p50 and p52. Unlike the three Rel proteins, p50 and p52 are 
produced through proteolytic processing from two inhibitory precursor 
proteins, NF-κB1/p105 and NF-κB2/p100 respectively. The NF-κB dimers 
remain transcriptionally inactive as long as associated with an NF-κB 
inhibitor protein, such as IκBα or the NF-κB2/p100 precursor protein. 
Signalling from GTP-bound Rac1 activates the IKK protein kinase 
complex resulting in the phosphorylation of both IκBα and NF-κB2/p100 
proteins. In addition, the inhibitory complexes are recruited to sites at the 
plasma membrane where Rac is activated and brings them into proximity 
with the SCF ubiquitin ligase complex (Boyer et al., 2004; Matos and 
Jordan, 2006). This leads to proteolytic degradation of IκBα and 
subsequent nuclear translocation of the transcriptionally competent 
RelA/p50 dimer (the canonical NF-κB pathway) but also promotes 
proteolytic processing of NF-κB2/p100 to p52, with subsequent 
transcriptional activation of RelB/p52 dimers (Matos and Jordan, 2006). 
The canonical, IκBα-regulated NF-κB pathway is also stimulated by 
Rac1b, an alternative splice variant that exists predominantly in the active 
GTP-bound state in cell lines (Jordan et al., 1999; Fiegen et al., 2004; 
Singh et al., 2004; Matos and Jordan, 2006). Whereas Rac1b does not 
activate several classical Rac signalling pathways, including lamellipodia 
formation or the activation of PAK1 or JNK activities, it retains the ability to 
induce IκBα phosphorylation, nuclear translocation of RelA and 
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transcriptional stimulation of luciferase reporter constructs containing 
either a consensus NF-κB binding motif or the native cyclin D1 promoter 
(Matos et al., 2003; Matos and Jordan, 2006; Esufali et al., 2007).  
BCL-6 is a transcriptional repressor (Seyfert et al., 1996) and was 
identified as one of the most frequently translocated genes in B-cell non 
Hodgkin’s lymphomas (Dalla-Favera et al., 1999; Staudt et al., 1999). 
BCL-6 contains carboxy-terminal zinc finger modules that bind DNA in a 
sequence-specific manner, especially the high affinity site 
TTCCT(A/C)GAA (Chang et al., 1996; Huynh and Bardwell, 1998). The 
genes repressed by BCL-6 in germinal centre B cells are involved in 
lymphocyte activation and differentiation, immunoglobulin (Ig) isotype 
switching, and regulation of inflammation or cell cycle progression (Shaffer 
et al., 2000; Dent et al., 2002; Niu, 2002). The repressor activity of BCL-6 
can be regulated by post-translational modifications. Both acetylation and 
phosphorylation events were shown to downregulate BCL-6 ability to 
repress transcription, the former impairing its recruitment of histone 
deacetylases (HDACs) (Bereshchenko et al., 2002), and the latter leading 
to its proteasomal degradation (Niu et al., 1998; Phan et al., 2007).  
Here we describe a novel link of Rac1 signalling to the regulation 
of gene transcription. We found that the transcriptional repressor BCL-6 is 
inhibited in colorectal tumour cells following Rac1 activation. This leads to 
increased expression of endogenous BCL-6-regulated genes including 
NFKB1/p105, the p50 precursor, and the cell adhesion molecule CD44. 
The mechanism of BCL-6 inactivation requires PAK1-mediated 
phosphorylation of BCL-6 downstream of Rac1 and is not triggered by 
splice variant Rac1b. 
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2.3. Material and Methods 
 
2.3.1. Cell culture and transfection  
 
DLD-1 colorectal cells were maintained in Dulbecco’s minimal 
essential medium (DMEM) supplemented with 10% (v/v) foetal bovine 
serum (FBS) (all reagents from Gibco, Carlsbad, CA, USA) and regularly 
checked for absence of mycoplasm infection. Cells were transfected at 60 
to 80% confluence using LipofectAMINE 2000 (Invitrogen, Carlsbad, CA, 
USA), according to the manufacturer’s instructions, and analysed 16-20 h 
later. Total amounts of transfected plasmid DNA were 4 µg per 60-mm 
dish for immunoprecipitation and 2 µg of DNA per 35-mm dish for 
immunofluorescence, cell fractionation and reporter assays. Transfection 
efficiency in DLD-1 cells was 50 to 70% as judged microscopically by 
expression of 2 µg of green fluorescent protein (GFP) expression vector. 
For RNA interference experiments, DLD-1 cells at 30 to 40% confluence 
were transfected in 35-mm dishes with 200 pmol of the indicated small 
interfering RNAs (siRNAs) using LipofectAMINE 2000 (Invitrogen), 
transfected again after 24 h with expression vectors or reporter constructs, 
and analysed 24 h later. The pre-designed siRNA oligonucleotides were 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA) with the following 
references: αPAK siRNA (sc-29700), γPAK siRNA (sc-36183), BCL-6 
siRNA (sc-29791), and a scramble control oligonucleotide (5’-AGG UAG 
UGU AAU CGC CUU GTT) from Eurofins MWG Operon (Ebersberg, 
Germany). For drug treatments, cells were incubated for 16 to 20 h with 
200 µM Rac inhibitor NSC23766 (Calbiochem, Darmstadt, Germany) or 
with 25 µM NADPH-oxidase inhibitor diphenyleneiodonium chloride (DPI) 
(Sigma, St. Louis, MO, USA), or 10 µM PAK inhibitor IPA-3 (Calbiochem). 
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2.3.2. DNA plasmids and constructs 
 
The following published constructs were received as gifts: 
pcDNA3-HA-IκBα (A32A36) from M. Karin (University of California, San 
Diego, CA, USA), pcDNA3-HA-RelB from C. V. Paya (Mayo Clinic, 
Rochester, MN, USA), SAPKβ-MKK7 from U. Rapp (Würzburg, Germany), 
PAK1-wt, PAK1-K299R and PAK1-T423E from J. Chernoff (Fox Chase 
Cancer Center, Philadelphia, PA, USA), the 3x-κB-luc vector (three copies 
of the Igκ-κB-motif immediately upstream of the β-globin TATA-box) 
(Lernbecher et al., 1993) from B. Baumann (University of Ulm, Germany) 
and the 5xBCL-6-vector and the pGL3 control vector (Huynh et al., 2000) 
from V.J. Bardwell (University of Minnesota, Minneapolis, MN, USA). Rac1 
and Rac1b cDNAs as well as their Q61L mutants were subcloned as an 
EcoRI/BamHI fragment into pcDNA3-Myc, pEGFP (Clontech, Mountain 
View, CA, USA) and pDsRed-C1 (Clontech) vectors as previously 
described (Matos et al., 2003; Matos and Jordan, 2006). For their 
subcloning into pDsRed-C1 (Clontech), the respective pEGFP vectors 
were cut using the EcoRI/BamHI restriction sites. pEGFP-BCL-6 was 
generated by PCR amplification of the BCL-6 cDNA from pmT2T-HA-
BCL6, provided by R. Dalla-Favera (Columbia University, New York, NY, 
USA), using a forward primer (5’-GGT ACC ATG GCC TCG CCG GCT 
GAC A) and a reverse primer (5’-TCA GCA GGC TTT GGG GAG CT), 
followed by subcloning into pEGFP-C3 using KpnI and SmaI. All PAK1 
constructs were subcloned into pEGFP-C3 vector using HindIII/EcoRI 
restriction sites. All constructs were confirmed by automated DNA 
sequencing. 
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2.3.3. Analysis of transcript expression and semi-quantitative 
reverse transcription-PCR (RT-PCR)  
 
Total RNA was extracted from cell lysates with the RNeasy kit 
(Qiagen, Hilden, Germany) and 1 µg reverse transcribed using random 
primers (Invitrogen) and Ready-to-Go You-Prime First-Strand Beads (GE 
Healthcare, Buckinghamshire, UK). The primers (F*, forward; R*, reverse) 
for the specific amplification of BCL-6 were BCL6-F* (5’- AGA GCC CAT 
AAA ACG GTC CT) and BCL6-R* (5’-AGT GTC CAC AAC ATG CTC CA); 
for NFKB1 were p105-F* (5’-CCT GGA TGA CTC TTG GGA AA) and 
p105-R* (5’-TCA GCC AGC TGT TTC ATG TC); for CD44 were        
CD44-F* (5’-TCT GTG CAG CAA ACA ACA CA) and CD44-R* (5’-TAG 
GGT TGC TGG GGT AGA TG); for PAK1 were PAK1-444F* (5’-GTC AGC 
TGA GGA TTA CAA TTC) and PAK1-661R* (5’-GAG ATG TAG CCA CGT 
CCC GAG); for PAK2 were PAK2-431F* (5’-CTC CTG AGA AAG ATG 
GCT TTC) and PAK2-632R* (5’-ACA TGT GAA TCA CCA ACT GGT); for 
PAK3 were PAK3-437F* (5’-GTG CAC ATG GAT ACA TAG CAG) and       
PAK3-663R* (5’-TGT GAC CTC TTT ATT TGG TAC); for BAZF were       
BAZF-e1F* (5’-AGA GCA CAC AAG GCA GTT CTC) and BAZF-e2R*   
(5’-GTG CAG TGG CTG GAG AGA GG); and for RNA polymerase II    
(Pol II) were Pol II-F* (5’-GAG CGG GAA TTT GAG CGG ATG C) and   
Pol II-R* (5’-GAA GGC GTG GGT TGA TGT GGA AGA). Amplification 
reactions were performed using AmpliTaq polymerase (Perkin-Elmer, 
Waltham, MA, USA) using the following basic program: 30 s at 94ºC, 30 s 
at the annealing temperature, and 30 s at 72ºC. The annealing 
temperature and number of cycles for each PCR were as follows: 58ºC 
and 30 cycles for BCL-6, 64ºC and 30 cycles for BAZF, 56ºC and           
29 cycles for PAK1 and PAK2, 58ºC and 35 cycles for PAK3, 58ºC and  
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28 cycles for NFKB1, 60ºC and 30 cycles for CD44, and 64ºC and          
28 cycles for Pol II. All reactions included an initial denaturation step of 5 
min at 94ºC and a final extension step of 10 min at 72ºC. To allow a semi-
quantitative analysis of transcript levels, all amplification conditions were 
experimentally optimised to correspond to the linear amplification phase, 
using serial dilutions of control cDNAs. The products were separated on 
2% agarose gels containing ethidium bromide and band intensities were 
quantified on digitalised images using ImageJ software (National Institutes 
of Health – NIH) followed by normalization to Pol II expression levels. No 
amplification was obtained when RNA was mock reverse transcribed 
without adding reverse transcriptase. 
 
2.3.4. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blotting 
 
Samples were boiled for 10 min, centrifuged briefly and resolved in 
10 to 15% SDS-PAGE mini-gels. Proteins were transferred onto 
polyvinylidene difluoride (PVDF) membranes using a Mini Trans-Blot cell 
(Bio-Rad; Hercules, CA, USA). Membranes were blocked in Tris-buffered 
saline (TBS), 0,1% Triton X-100, 5% milk powder, probed using the 
indicated antibodies, and then incubated with a secondary peroxidase-
conjugated antibody (BioRad) followed by chemiluminescence detection. 
The antibodies used for Western blots were as follows: polyclonals anti-
Histone H2B (sc-10808), anti-BCL-6 clone N3 (sc-858) and anti-c-Myc 
clone A14 (sc-789) from Santa Cruz Biotechnology; monoclonal anti-Rac1 
clone 23A8 from Upstate Biotechnologies (#05-389; Charlottesville, 
Virginia, USA); polyclonal anti-hemagglutinin (anti-HA; H6908) and 
monoclonal anti-α-tubulin clone B-5-1-2 (as a loading control; T6074) from 
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Sigma; polyclonal anti-GFP (ab290) and monoclonal anti-PAK1 (ab40795) 
from Abcam (Cambridge, UK); polyclonal anti-PAK1/2/3 from Cell 
Signaling Technology (#2604; Danvers, MA, USA); and polyclonals     
anti-p50 (HM1238) and anti-RelA (HM1240) from Hypromatrix (Worcester, 
MA, USA). For densitometric analysis, films from at least three 
independent experiments were digitalized and analysed using ImageJ 
software (NIH). 
 
2.3.5. Immunoprecipitation 
 
Approximately 2 x 106 DLD-1 cells were seeded in 60-mm dishes, 
transfected as indicated, and assayed 16 to 20 h later. For co-precipitation 
experiments, cells were washed in cold PBS and lysed on ice in 250 µl of 
lysis buffer (50 mM Tris-HCl [pH 7.5], 1% [v/v] Nonidet P-40 (NP-40),    
100 mM NaCl, 10% [v/v] glycerol, 5 mM MgCl2, and a protease inhibitor 
cocktail [Sigma]). Total lysates were then sonicated on ice (10 pulses of 
20 s at 40% power on a Sonics Vibra Cell sonicator) and cleared by 
centrifugation at 2,500 x g for 5 min. An aliquot of 0.1 volume was added 
to 5x Laemmli sample buffer. The remaining lysate was incubated for 1 h 
at 4ºC with mouse monoclonal anti-c-Myc clone 9E10 (M5546; Sigma) or 
anti-GFP (ab1218; Abcam) antibodies at 2 µg ml-1, pre-coupled to protein 
G-agarose beads (Roche Applied Science, Penzberg, Germany). Beads 
were then washed five times with an excess of lysis buffer containing   
300 mM of NaCl and the precipitated protein complexes were solubilised 
in 2x Laemmli sample buffer and analysed on Western blots as described 
above. Immunoprecipitation of protein substrates for in vitro kinase assays 
followed the same methodology, except that cell lysis was performed 
using radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl    
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[pH 7.5], 1% [v/v] NP-40, 150 mM NaCl, 0,5% [w/v] sodium deoxycholate, 
0,1% [w/v] SDS, and a protease inhibitor cocktail [Sigma]). All results were 
confirmed in at least three independent experiments.  
 
2.3.6. Cell fractionation  
 
Nuclear proteins were separated into a soluble pool not retained in 
the nucleus and into a chromatin-bound insoluble pool according to 
previously described procedures (Solan et al., 2002). Briefly, cells were 
washed in cold phosphate-buffered saline (PBS), scraped off and lysed on 
ice for 10 min in 200 µl of fractionation buffer (50 mM Tris-HCl [pH 7.9], 
0.1% [v/v] NP-40, 1.5 mM MgCl2, 10 mM KCl, and a protease inhibitor 
cocktail [Sigma]). The soluble fraction was collected by centrifuging the 
lysate at 3,500 × g for 5 min and adding the supernatant to 50 µl of         
5x Laemmli sample buffer. The pellet containing the insoluble nuclear 
fraction was washed once in fractionation buffer and then resuspended in 
250 µl of 1x Laemmli sample buffer supplemented with 5 mM MgCl2 and 
50 U endonuclease (Benzonase, Sigma) to digest nucleic acids. Equal 
volumes of both fractions were analysed side by side on Western blots. 
Results were confirmed in at least three independent experiments. 
 
2.3.7. Confocal immunofluorescence microscopy 
 
Cells were grown on glass cover slips (10 by 10 mm), transfected 
and incubated as indicated above, then washed twice in PBS, immediately 
fixed with 4% (v/v) formaldehyde in PBS for 30 min at room temperature, 
and subsequently permeabilized with 0.2% (v/v) Triton X-100 in PBS for 
10 min at room temperature. Myc-tagged PAK (Myc-PAK) was detected 
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with mouse anti-c-Myc clone 9E10 (Sigma), followed by goat anti-mouse 
TexasRed (Jackson ImmunoResearch Laboratories, West Grove, 
PA, USA). Cells were then briefly stained with 0.5 ng/ml 4',6-diamidino-2-
phenylindole (DAPI) (Sigma) and washed in PBS, and the cover slips 
mounted in VectaShield (Vector Laboratories, Burlingame, CA, USA) and 
sealed with nail polish. Images were recorded with the 405-nm, 488-nm 
and 532-nm laser lines of a Leica TCS-SPE confocal microscope and 
processed with Leica and Adobe Photoshop software. 
 
2.3.8. Luciferase reporter assay 
 
Approximately 5 x 105 DLD-1 cells were seeded in 35-mm dishes, 
transfected with 50 ng of the pRL-TK luciferase reporter (for constitutive 
expression of Renilla luciferase as internal control; Promega, Fitchburg, 
WI, USA) and 1 µg of either standard NF-κB or pGL3-5xBCL-6 or pGL3 
control reporter. For experiments titrating individual proteins, 500 to   
1,000 ng of the indicated construct was co-transfected, whereas for the           
co-expression of two proteins the amount of construct was previously 
adjusted to yield comparable expression levels. At 16 to 20 h post-
transfection in the absence or presence of the NADPH oxidase inhibitor 
DPI (Sigma) or the Rac inhibitor NSC23766 (Calbiochem), cells were 
lysed, assayed with the Dual-Luciferase reporter assay (Promega) 
following the manufacturer’s instructions, and measured in an Anthos 
Lucy-2 luminometer. Lysates were assayed in duplicate samples and 
additional aliquots were analysed by Western blotting to document protein 
expression levels. All firefly luciferase values were first normalized to the 
internal control values obtained for Renilla luciferase and then plotted as 
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the increase over the value of untreated or vector control. The values 
displayed were from at least three independent transfection assays. 
 
2.3.9. In vitro protein kinase assays 
 
For in vitro protein kinase assays, either 1 µg of a recombinant 
fragment of human BCL-6 (amino acids 3 to 484 lacking the C-terminal 
zink finger domains) (sc-4105; Santa Cruz Biotechnology) or the beads 
containing immunoprecipitated GFP-tagged BCL-6 (GFP-BCL-6) protein 
were resuspended in 20 µl of kinase reaction buffer (30 mM Tris-HCl    
[pH 7.5], 10% [v/v] glycerol, 1 mM dithiothreitol (DTT), 1 mM Na3VO4,   
37.5 mM MgCl2 and 250 µM ATP) and incubated in the presence of          
5 µCi [γ-32P] ATP at 30ºC for 60 min with 25, 50, 100, or 200 ng 
recombinant PAK1 (#0357-0000-1; ProQuinase, Freiburg, Germany). 
Then, 5x Laemmli sample buffer was added to the reaction mixtures, and 
proteins were separated by SDS-PAGE and then transferred to PVDF 
membrane. The membrane was first analysed by autoradiography, 
followed by Western blotting using the indicated antibodies. 
 
2.4. Results 
 
2.4.1. Rac1 activation leads to an increase in NFKB1/p50 protein 
levels 
 
Previously we reported that Rac1 signalling stimulates NF-κB 
transcriptional activity through both the canonical RelA/p50 pathway and 
the RelB/p52 dependent pathway in colorectal cells (Matos and Jordan, 
2006). In the course of these studies, we noticed that the expression of 
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active Rac1 not only increased NF-κB reporter vector activity but also the 
protein level of p50, whereas expression of its dimerization partner RelA 
remained unaffected (Fig. 2.1). Moreover, we observed that p50 levels 
decreased when activation of endogenous Rac1 was repressed by the 
inhibitor NSC23766 (Gao et al., 2004).  
The p50 subunit is produced through constitutive proteolytic 
processing of the precursor protein p105, which is transcribed from the 
NFKB1 gene. A previous report has shown evidence that the NFKB1 gene 
promoter could be stimulated by RelA/p50 itself in hematopoietic cells 
(Cogswell et al., 1993). In order to test whether the RelA complex is 
involved in regulating NFKB1/p50 expression in colorectal cells, we first 
co-transfected DLD-1 cells with expression vectors encoding a 
constitutively active Rac1-L61 mutant and the non-degradable super-
repressor IκBα (A32A36) (DiDonato et al., 1996), which inhibits RelA/p50 
activation. We found that the presence of the super-repressor significantly 
inhibited the Rac1-mediated activation of the NF-κB transcriptional 
reporter, but the increase in p50 levels was still detected (Fig. 2.1). This 
increase in p50 was also observed when the Rac1-mediated production of 
ROS, an upstream event of RelA/p50 activation, was inhibited by the 
NADPH oxidase inhibitor DPI.  
 
2.4.2. Rac1 regulates NFKB1 expression by releasing BCL-6-
mediated transcriptional repression 
 
A previous report has demonstrated that the NFKB1 promoter 
contains binding sites for the transcription factor BCL-6  (Li et al., 2005),  a   
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Figure 2.1. Rac1 activation modulates NFKB1/p50 protein levels. DLD-1 
colorectal cells were transfected or treated with drug as indicated in the figure           
(+, transfected or treated with drug; −, not transfected or treated with drug) and 
lysed 24 h later. In one lysate aliquot, the luciferase activity of the co-transfected 
NF-κB reporter plasmid was measured, whereas in another aliquot, the indicated 
protein levels were determined by Western blotting. Note that the presence of an 
active Rac1 mutant was particularly efficient in stimulating reporter gene activity 
and in increasing p50 protein levels, while the amount of RelA remained 
unchanged (tubulin levels served as a loading control). Whereas reporter gene 
transcription was strongly inhibited by DPI (inhibitor of NADPH oxidase and ROS 
formation) or by the super-repressor IκBα (A32A36), both treatments had no 
effect on the Rac1-L61-stimulated p50 increase. (NSC23766 is an inhibitor of 
endogenous Rac1 activation).  
 
repressor identified in B-cell lymphoma (Seyfert et al., 1996; Dalla-Favera 
et al., 1999; Staudt et al., 1999). In addition, a highly related repressor 
protein, BAZF/BLC6b, has been identified (Sakashita et al., 2002), which 
binds the same promoter sites as BCL-6. To analyse the contribution of 
Chapter 2
 
	  86 
both factors to NFKB1 expression, we first determined by RT-PCR 
whether endogenous  BCL-6  and  BAZF  transcripts  were  expressed  in 
three colorectal cell lines as well as in the B-cell precursor leukemia 697 
cell line and erythroleukemia HEL cells as positive controls. We found 
endogenous BCL-6 transcript expression in the three colorectal and the 
erythroleukemia cell line, whereas BAZF transcript was expressed only in 
HEL cells (Fig. 2.2A). These data identified BCL-6 as a candidate 
regulator of NFKB1/p50 expression in colorectal cells, prompting us to 
transfect cells with increasing amounts of an expression vector encoding 
the BCL-6 protein. Intriguingly, the endogenous NFKB1 transcript 
expression (Fig. 2.2B), as well as the corresponding NFKB1/p50 protein 
levels (Fig. 2.2C), were clearly inhibited by the expression of BCL-6. In 
contrast, expression of active Rac1 led to increased expression of both 
the NFKB1 transcript (Fig. 2.2B) and NFKB1/p50 protein (Fig. 2.2C). 
Conversely, when the endogenous Rac1 activation in DLD-1 cells was 
impaired by treating cells with the Rac inhibitor NSC23766, expression of 
NFKB1 transcript and NFKB1/p50 protein was inhibited (Fig. 2.2B and 
2.2C). These data indicated that Rac1 signalling could modulate NFKB1 
gene expression via the transcriptional repressor BCL-6.  
 In order to test whether Rac1 activation can regulate the 
transcriptional activity of BCL-6, we utilized a previously described      
BCL-6-controlled reporter gene (Huynh et al., 2000). When this reporter 
was co-expressed with BCL-6, a clear repression of transcriptional activity 
was observed (Fig. 2.3A). Repression was also evident when activation of 
endogenous Rac1 was inhibited with NSC23766. In contrast, 
transcriptional activity of the reporter was clearly promoted by siRNA-
mediated depletion of endogenous BCL-6 or upon co-transfection with 
Rac1-L61, in  a  dose-dependent  manner (Fig. 2.3A).  These data provide   
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Figure 2.2. Rac1 modulates NFKB1 expression via BCL-6. (A) The expression 
of endogenous BCL-6 and the highly related repressor protein BAZF/BLC6b was 
tested by RT-PCR in three colorectal cell lines and three hematopoietic cell lines, 
as indicated. The amplification of RNA polymerase II (Pol II) served as internal 
control. (B and C) Role of BCL-6 overexpression or modulation of Rac1 signalling 
in NFKB1/p50 expression. DLD-1 cells were transfected with either GFP control 
vector versus increasing amounts (indicated by the height of the black triangle) of 
GFP-BCL-6, or with Myc control vector versus increasing amounts of Myc-Rac1-
L61, or mock transfected and treated with the Rac1 inhibitor NSC23766. Cells 
were lysed following 24 h to isolate either total RNA or whole protein. (B, left 
panel) NFKB1 or control Pol II transcripts were amplified by semi-quantitative 
RT-PCR, and (right panel) band intensities were quantified from digital images by 
densitometry. (C, left panel) Western blot showing NFKB1/p50 protein levels as 
well as levels of transfected GFP-BCL-6 or Myc-Rac1-L61. (B and C, right 
panels) Detection of endogenous Rac1 served as a loading control, and band 
intensities were quantified by densitometry. Symbols: +, transfected or treated 
with drug; −, not transfected or treated with drug. α-GFP, anti-GFP antibody. 
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substantial evidence that Rac1 signalling regulates gene expression via   
BCL-6. Interestingly, we observed that the splice variant Rac1b could not 
significantly affect the BCL-6-controlled reporter gene (Fig. 2.3A).  
We next asked whether another endogenous BCL-6 target gene, 
the cell adhesion molecule CD44 (Shaffer et al., 2000), was modulated by 
Rac1 activation in DLD-1 cells. We observed that ectopic expression of 
BCL-6 or inhibition of endogenous Rac1 activity led to decreased CD44 
transcript expression, whereas transfection of Rac1-L61 promoted an 
increase (Fig. 2.3B). Together, our results strongly indicate that Rac1 
activation releases BCL-6 repression from target genes including NFKB1, 
CD44 and a BCL-6-specific luciferase reporter. 
 
2.4.5. Active Rac1 induces nuclear redistribution and chromatin 
release of BCL-6 
 
In order to obtain mechanistic insights into how Rac1 activation 
would influence BCL-6 activity, we first studied its effect on the subcellular 
localization of BCL-6 using immunofluorescence microscopy and cell 
fractionation. As shown in Figure 2.4A, the expression of BCL-6 alone 
revealed a strictly nuclear localization in DLD-1 cells with the typical 
concentration of BCL-6 in numerous nuclear dots that has previously been 
described (Cattoretti et al., 1995; Huynh et al., 2000). In the presence of 
Rac1-L61, BCL-6 lost accumulation in nuclear dots and appeared diffuse 
in the nucleoplasm. In contrast, splice variant Rac1b-L61 had little effect 
on the accumulation of BCL-6 in dots in the nucleus (Fig. 2.4A). This is in 
agreement with the poor stimulation of the BCL-6-controlled reporter gene 
that we observed for Rac1b-L61 (Fig. 2.3A).  
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Figure 2.3. Rac1 releases transcriptional repression by BCL-6. (A) DLD-1 
cells were transfected with a transcriptional luciferase reporter vector under the 
control of five consensus BCL-6 binding motifs (Huynh et al., 2000) or the 
respective empty pGL3 control vector. Cells were co-transfected with the 
indicated expression vectors and siRNAs or mock transfected and treated with 
the Rac1 inhibitor NSC23766. The increasing or decreasing amount of vector is 
indicated by the height of the black triangle. (B) Effect of BCL-6 or Rac1 signalling 
on the endogenous BCL-6 target gene CD44. (Left panel) Cells were treated as 
described in the legend to Figure 2.2, CD44 or control Pol II transcripts were 
amplified by semi-quantitative RT-PCR and band intensities were quantified from 
digital images by densitometry (right panel). Symbols: +, transfected or treated 
with drug; −, not transfected or treated with drug. siBCL-6, BCL-6-specific siRNA.   
 
 To test whether these differences in localization would represent 
altered chromatin binding, we applied a previously described cell 
fractionation protocol (Kazansky et al., 1999; Dhordain et al., 2000; Solan 
et al.,  2002),  which separates transcription factors into a soluble pool that 
is extracted from the nucleus and into a chromatin-bound pool that 
remains insoluble. Under these experimental conditions, the expression of 
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BCL-6 alone revealed the majority of the protein in the insoluble 
chromatin-bound fraction (Fig. 2.4B). This is compatible with its role as a 
transcriptional repressor and corroborates the inhibition of NFKB1 and 
CD44 gene expression observed in Figures 2.2B and 2.3B. When we 
determined the fractionation of BCL-6 in cells co-expressing an active 
mutant of the splice variant Rac1b, only a very small increase in the 
soluble fraction was observed. In contrast, co-expression of activated 
Rac1 led to a remarkable transition of BCL-6 from the chromatin-bound 
insoluble fraction into the soluble pool (Fig. 2.4B). In these experiments, 
the total amount of BCL-6 protein apparently remained unaffected. 
 Altogether, these data demonstrate that upon activation of Rac1, 
the transcription factor BCL-6 becomes relocalized within the nucleus, is 
no longer retained in the chromatin-bound fraction and loses its activity to 
repress target genes.   
 
2.4.6. Modulation of BCL-6 by Rac1 signalling requires PAK1 
 
For further insights into the effect of Rac1 on BCL-6 activity, we 
tested the interaction of Rac1 and BCL-6 by co-immunoprecipitation. 
Whereas Rac1-L61 co-precipitated with RelB, in agreement with 
previously described data (Matos and Jordan, 2006), we found no 
evidence for the formation of a stable complex between BCL-6 and active 
Rac1 under the same experimental conditions (Fig. 2.5). The lack of 
interaction between Rac1 and BCL-6 suggested that Rac1 affects BCL-6 
activity indirectly through a downstream signalling pathway.  
The generation of ROS through the stimulation of NADPH oxidase 
activity is a Rac function conserved in immune and epithelial cells. 
Moreover, ROS are known to modulate the activity of several transcription    
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Figure 2.4. Active Rac1 affects subnuclear location and chromatin binding 
of BCL-6. (A) DLD-1 cells were co-transfected with GFP-BCL-6 and either DsRed 
empty vector, DsRed-Rac1-L61 or DsRed-Rac1b-L61 as indicated. Cells were 
fixed after 24 h, nuclei were counterstained with DAPI, and fluorescent signals 
were recorded by confocal microscopy. (B) Presence of BCL-6 in a soluble or 
chromatin-bound form. DLD-1 cells were co-transfected with GFP-BCL-6 and the 
indicated Myc-tagged vectors and lysed after 24 h so that a soluble (S) and a 
non-soluble (NS), chromatin-bound fraction was obtained. Western blot analysis 
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of these fractions is shown. Histone 2B was detected as a marker for insoluble 
chromatin-bound proteins, and β-tubulin was detected as a marker for soluble 
factor. α-GFP, anti-GFP antibody; α-Myc, anti-Myc antibody. 
  
factors (Wu, 2006), including NF-κB downstream of Rac1 and Rac1b 
(Matos and Jordan, 2006). We therefore treated Rac1-L61-expressing 
cells with DPI, a cell-permeable inhibitor of the NADPH oxidase widely 
used to block the generation of ROS (Sulciner et al., 1996; Sundaresan et 
al., 1996; Bonizzi et al., 1999; Matos and Jordan, 2006). We found that, 
although this treatment clearly inhibited activation of an NF-κB-driven 
luciferase reporter (Fig. 2.1), it had no effect on the increase in the     
BCL-6-driven reporter activity (Fig. 2.6A).  
 In order to determine whether the observed modulation of BCL-6 
repression was Rac1 specific, we compared the effects of activated RhoA, 
Rac1, and Cdc42. We found that active Cdc42 also produced a moderate 
but significant stimulation of the BCL-6 reporter (Fig. 2.6A).  
 
Figure 2.5. Active Rac1 
and BCL-6 are not found 
in a protein complex.  
DLD-1 cells expressing Myc- 
control vector or Myc-Rac1-
L61 were co-transfected with 
either GFP-BCL-6 or GFP-
RelB. Whereas RelB co-
immunoprecipitated with 
Myc-Rac1-L61, confirming 
previously described data 
(Matos and Jordan, 2006), 
no such complex was 
detected between Rac1-L61 
and BCL-6. IP: α-Myc, 
immunoprecipitation with 
anti-Myc antibody; Pre-IP, 
pre-immunoprecipitation.  
 
Rac1 modulates transcriptional repression by BCL-6
 
	   93 
 Stimulation of the protein kinases PAK and JNK are two classical 
downstream pathways that are stimulated by Rac1 and Cdc42, but not by 
RhoA or by the Rac1b splice variant (Matos et al., 2003; Singh et al., 
2004), both of which failed to inhibit BCL-6 activity (Fig. 2.6A). Thus, the 
activity of the BCL-6 luciferase reporter was analysed in cells transfected 
with previously described constitutively active mutants of JNK       
(SAPKβ-MKK7) (Rennefahrt et al., 2002) and PAK1 (PAK1-T423E) (Sells 
et al., 1997). As shown in Fig. 2.6A, active JNK had no effect, whereas the   
expression of constitutively active PAK1 significantly stimulated 
transcription from the BCL-6 reporter. We further determined whether the 
catalytic activity of PAK1 was involved in the observed BCL-6 reporter 
stimulation. The reporter vector was co-transfected with active Rac1-L61 
in the presence of a dominant-negative, kinase-dead PAK1 mutant 
(PAK1-K299R) (Sells et al., 1997). These experiments revealed a clear 
reduction in Rac1-mediated transcriptional stimulation (Fig. 2.6A), 
suggesting that the Rac1-L61-stimulated transcription from the BCL-6 
reporter required Rac1-induced PAK activation.  
GTP-bound Rac1 can activate PAK1 (α-PAK), PAK2 (γ-PAK), and 
PAK3 (β-PAK). Thus, we determined which endogenous PAK isoform 
could be mediating the observed effects downstream of active Rac1 in 
DLD-1 cells. Using RT-PCR, we found that only PAK1 and PAK2 
transcripts were expressed in colorectal cells, whereas PAK3 transcript 
was detected in a glioblastoma cell line (Fig. 2.6B). In order to directly 
compare the expression levels of PAK1 and PAK2, colorectal cell lysates 
were analysed by Western blotting using an anti-PAK1/2/3 antibody. We 
found that PAK1 was by far the most prominent isoform expressed (Fig. 
2.6C).  We then determined whether the Rac1-L61 stimulated transcription 
from  the   BCL-6   reporter  required  endogenous  PAK1.   Expression  of  
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Figure 2.6. PAK1 acts downstream of Rac1 in the release of transcriptional 
repression by BCL-6. (A) DLD-1 cells were transfected with the transcriptional 
BCL-6 luciferase reporter vector and one of the indicated GFP-tagged expression 
vectors encoding either activated small GTPase mutants or protein kinase 
mutants. Luciferase activity was determined in cell lysates and expression of 
transfected proteins was documented by Western blotting. A graph with the 
observed changes in luciferase activity relative to GFP empty vector-transfected 
control cells (top panel) and immunoblots with the expression levels of the GFP-
tagged proteins (middle panel) and β-tubulin as a loading control (bottom panel) 
are shown. The migration of molecular weight markers is indicated. Note that 
transcriptional repression by BCL-6 was released in the presence of Rac1-L61, 
Cdc42-V12 and a constitutively active (ca) PAK1 mutant, whereas a kinase-dead 
(kd) PAK1 prevented the Rac1-L61 mediated increase in luciferase activity. (B) 
RT-PCR analysis to determine the expression of PAK1, PAK2, and PAK3 in  
DLD-1 and HT29 colorectal cells compared to SW1088 glioblastoma cells. (C) 
Western blot analysis to directly compare the expression levels of PAK1 and 
PAK2 in DLD-1 or HT29 cells using an anti-PAK1/2/3 antibody. Note that PAK1 is 
the most prominent isoform expressed. Symbols: +, transfected or treated with 
drug; −, not transfected or treated with drug. 
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endogenous PAK1 or endogenous PAK2 was depleted by transfection of 
cells with specific siRNAs. As shown in Fig. 2.7A, these oligonucleotides 
specifically depleted either PAK1 or PAK2, however, only the depletion of   
PAK1 affected both the endogenous and the Rac1-L61-stimulated  
5xBCL-6 activation (Fig. 2.7B). In addition, prior incubation of DLD-1 cells 
with IPA-3, a specific inhibitor that prevents activation of group I PAKs by 
allosteric targeting of their autoregulatory domain, blocked the effect of 
Rac1-L61 on the 5xBCL-6 reporter (Fig. 2.7B). In these experiments, no 
detectable changes in the total amount of BCL-6 protein were observed. 
Altogether, these data indicate that PAK1 is a critical link between 
Rac1 activation and transcriptional repression by BCL-6.  
 
Figure 2.7. Interference with PAK1 by depletion or inhibitor treatment blocks 
Rac1-mediated activation of BCL-6. (A) Western blot showing the efficiency 
and specificity of PAK1- or PAK2-specific siRNAs transfected into DLD-1 cells. 
Detection of β-tubulin served as a loading control. (B) DLD-1 cells were 
transfected with the indicated siRNAs and 24 h later transfected again with the 
5xBCL-6 transcriptional luciferase reporter vector in the presence (+) or absence 
(−) of Rac1-L61. When indicated, cells were incubated with 10 µM PAK inhibitor 
IPA-3. Symbols: +, transfected or treated with drug; −, not transfected or treated 
with drug. Ctrl, control.  
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2.4.7. PAK1 binds to and phosphorylates BCL-6 
 
 Since PAK1 overexpression stimulated the BCL-6 reporter, we 
used immunofluorescence microscopy to test whether PAK1 could also 
affect the nuclear redistribution of BCL-6 observed in the presence          
of active Rac1. As shown in Fig. 2.8A, overexpression of the kinase-dead 
Myc-PAK1-K299R mutant apparently enhanced the dot-like localization 
pattern of BCL-6 in the nucleus, whereas overexpression of a           
kinase-competent PAK1 redistributed BCL-6 to a more diffuse 
nucleoplasmic pattern (Fig. 2.8B). In addition, the expression of PAK1 
decreased the amount of BCL-6 remaining in the insoluble         
chromatin-bound cell fraction, whereas kinase-dead PAK1 did not affect     
chromatin-binding (Fig. 2.8C). PAK1 also clearly localized to the nucleus. 
In fact, we observed a correlation between the expression level of BCL-6 
and the recruitment of PAK1 from the cytoplasm into the nucleus. In 
particular, a pixel intensity analysis in confocal images revealed that cells 
with an equivalent overall level of ectopic PAK1 expression (Fig. 2.8D, top 
graph) differed in their nuclear PAK1 signal (Fig. 2.8D, bottom graph), 
depending on the expression level of BCL-6 (Fig. 2.8D, middle graph).  
The generation of pixel overlap maps from the confocal images 
allowed the calculation of Pearson's correlation values, which suggested 
colocalization between nuclear PAK1 and BCL-6 (data not shown). We 
thus analysed whether a PAK1/BCL-6 complex could be isolated by co-
immunoprecipitation from DLD-1 colorectal cells. Using the previously 
described co-precipitation of Rac1-L61 with PAK1 (Matos et al., 2003) as 
a positive control, we demonstrate that PAK1 can form a stable complex 
with BCL-6 (Fig. 2.8E).  
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Figure 2.8. Effect of PAK1 on nuclear BCL-6. (A and B) DLD-1 cells were co-
transfected with GFP-BCL-6 and the kinase-dead Myc-PAK1-K299R mutant     
(A) or with wild-type Myc-PAK1 (B). The cells were fixed after 20 h and analysed 
by confocal microscopy. Note in panel A, the increase in nuclear dot localization 
of BCL-6 in the presence of dominant-negative PAK1 but the diffuse 
nucleoplasmic pattern with wild-type PAK1 in panel B. ROI 1, region of interest 1. 
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(C) Presence of BCL-6 in the chromatin-bound fraction. DLD-1 cells were co-
transfected with GFP-BCL-6 and the indicated Myc-tagged vectors and separated 
into a soluble (S) and a non-soluble (NS) chromatin-bound fraction, as described 
in the legend to Fig. 2.4B. (D) The intensity of the overall fluorescent PAK1 signal 
in the two representative cells shown in panel B, with different amounts of BCL-6 
expression, was determined (top panel, compare regions of interest ROI 1 and 
ROI 2) and found to be equivalent. Then the intensities of the nuclear versus 
cytoplasmic PAK1 and BCL-6 signals were compared along the axes indicted as 
ROI 3 and ROI 4. Note that the distribution of PAK1 signal between the nucleus 
and the cytoplasm (ROI 3 and ROI 4 in the red channel [bottom panel] correlates 
with the signal intensity of BCL-6 in the nucleus (ROI 3 and ROI 4 in green 
channel [middle panel]). (E) BCL-6 and PAK1 co-immunoprecipitate. DLD-1 cells 
were co-transfected with Myc-PAK1 and either GFP control vector or GFP-BCL-6 
or GFP-Rac1-L61 as a positive control. Cells were lysed after 24 h, extracts were 
incubated with anti-GFP antibodies (α-GFP) and the presence of co-precipitated 
Myc-PAK1 was analysed (top panel). Successful precipitation of GFP-tagged 
proteins (middle panel) as well as equal expression of Myc-PAK1 in total cell 
extracts (Pre-IP, bottom panel) is also shown. α-Myc, anti-Myc antibody. 
 
Since BCL-6 can be phosphorylated by mitogen-activated protein 
kinases (MAPKs) (Niu et al., 1998), we asked whether it could be a direct 
substrate for PAK1. Using an in vitro phosphorylation assay, we added 
increasing amounts of full-length, recombinant PAK1 to a recombinant 
484-amino acid fragment of the BCL-6 protein. Under these conditions, a 
concomitant increase of BCL-6 phosphorylation was observed (Fig. 2.9A, 
top panel), which generated electrophoretic band-shifts that were 
confirmed by Western blot analysis with an anti-BCL-6 serum (Fig. 2.9A, 
middle panel). These data suggest the presence of multiple 
phosphorylation sites for PAK1 in the BCL-6 fragment.  
 To confirm that PAK1 also phosphorylates the full-length protein, 
GFP-BCL-6 was immunoprecipitated from DLD-1 cells using stringent 
RIPA buffer conditions to avoid background phosphorylation events and 
then incubated in vitro with recombinant PAK1. As shown in Fig. 2.9B, full-
length GFP-BCL-6 became clearly phosphorylated by PAK1, although the 
higher  molecular  weight  of  the  GFP-tagged  protein  did  not  allow  the   
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Figure 2.9. PAK1 phosphorylates BCL-6. (A) A recombinant N-terminal BCL-6 
fragment (rBCL-6) and increasing amounts of recombinant PAK1 (rPAK1) were 
incubated in an in vitro protein kinase assay before proteins were separated by 
SDS-PAGE and transferred to PVDF membranes. Membranes were exposed to 
X-ray films (top panel), followed by sequential immunoblot detection of BCL-6 
(middle panel) and PAK1 (bottom panel). Note the shifts in electrophoretic 
migration of the phosphorylated rBCL-6 as well as of autophosphorylated PAK1 
bands. The presence (+) or absence (−) of rBCL-6 and the increasing amount of 
rPAK1 is indicated by the height of the black triangle or black rectangle. (B) GFP 
control vector or full-length GFP-BCL-6 were transfected into DLD-1 cells, 
immunoprecipitated with anti-GFP antibodies (α-GFP) using RIPA buffer and then 
incubated in vitro in the presence (+) or absence (−) of 200 ng rPAK1. Western 
blots to document successful protein precipitation (top panel) and the presence of 
rPAK1 (middle panel) are shown. The corresponding autoradiograph shows 
phosphorylation of GFP-BCL-6 by PAK1 as well as PAK1 autophosphorylation 
(bottom panel). (C) Detection of endogenous BCL-6 by Western blotting in DLD-1 
cells transfected with either BCL-6-specific siRNAs (siBCL-6) or control siRNA 
(siCtrl) in the presence or absence of Myc-PAK1. Two specific bands were 
detected, and the shift in electrophoretic migration upon transfection of PAK1 
indicates that the top BCL-6 band is endogenous phospho-BCL-6 (p-BCL-6) (bars 
show migration of 75- and 100-kDa markers). 
Chapter 2
 
	  100 
detection of possible band shifts. We then analysed whole-cell lysates and 
detected two BCL-6 protein bands of about 80 and 120 kDa by Western 
blotting, both of which became specifically depleted upon transfection of 
cells with BCL-6 siRNAs (Fig. 2.9C). The higher-molecular-mass band 
was clearly increased upon transfection of cells with PAK1, indicating a 
phosphorylation-dependent band shift of the endogenous BCL-6 protein. 
    
2.5. Discussion 
 
The main finding in this work is that Rac1 regulates the 
transcription factor BCL-6 via PAK1 and counteracts the repression of its 
target genes. 
The BCL-6 transcriptional repressor is one of the most frequently 
translocated genes in B-cell non-Hodgkin’s lymphomas (Dalla-Favera et 
al., 1999; Staudt et al., 1999). BCL-6 translocations do not alter the BCL-6 
coding sequence but associate the gene with other promoter region, such 
as the IgH enhancer, and this deregulates BCL-6 expression. Moreover, 
the activity of BCL-6 can be modulated through post-translational 
modifications. For instance, acetylation of lysine 379 downregulates its 
ability to repress transcription, probably due to impaired recruitment of 
histone deacetylases (Bereshchenko et al., 2002), while phosphorylation 
by MAPKs in B cells was shown to target BCL-6 for rapid degradation by 
the ubiquitin-proteasome pathway (Niu et al., 1998; Phan et al., 2007).  
More recently, evidence has accumulated that BCL-6 is also 
expressed in non-hematopoietic cells. Its expression was detected in 
olfactory sensory neurons (Otaki et al., 2005), in healthy skin and 
epidermal neoplasms (Kanazawa et al., 1997), in uroepithelial cells (Lin et 
al., 2003; Huang et al., 2007) and in epithelial cells of the mammary gland 
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(Logarajah et al., 2003). BCL-6 expression has also been detected in 
HeLa cells (Allman et al., 1996), and in this study, we document for the 
first time its expression in colorectal cells. 
Here we found that Rac1 signalling affects the subnuclear 
localization and transcriptional repressor activity of BCL-6 and 
demonstrated these effects using four different approaches. First, a 
reporter construct expressing the luciferase gene under the control of five 
BCL-6 binding sites immediately upstream of the simian virus 40 (SV40) 
promoter (Huynh et al., 2000) was used and shown to become repressed 
in cells co-transfected with BCL-6, as expected. Repression of reporter 
activity was further observed when endogenous Rac1 activation was 
diminished by treating cells with the Rac1-specific inhibitor NSC23766. In 
contrast, expression of an active Rac1 mutant led to increased luciferase 
activity. These data clearly indicate a modulation of BCL-6 in response to 
Rac1 signalling. Second, the expression of two previously described 
endogenous BCL-6 target genes, NFKB1 (Li et al., 2005) and CD44 
(Shaffer et al., 2000), was analysed. As was observed with the BCL-6 
reporter, overexpression of BCL-6 and inhibition of endogenous Rac1 
activation by NSC23766 decreased expression of these genes. In 
contrast, transfection of activated Rac1 increased their expression up to 2- 
and 2.6-fold, respectively. Third, we determined the subnuclear 
distribution of BCL-6, which has previously been reported to accumulate in 
characteristic nuclear foci (Cattoretti et al., 1995; Huynh et al., 2000). In 
the presence of active Rac1, a clear redistribution of BCL-6 from these 
nuclear foci to a more diffuse, homogenous nucleoplasmic localization 
was observed (Fig. 2.4A). Fourth, our cell fractionation studies corroborate 
these results by showing the transition of BCL-6 from an insoluble, 
chromatin-bound form into a soluble form in the presence of active Rac1 
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(Fig. 2.4B). Together, these data provide substantial evidence that BCL-6-
mediated gene repression is negatively regulated by Rac1 signalling. 
The mechanism of how Rac1 affects BCL-6 activity apparently 
does not involve formation of a stable complex between BCL-6 and active 
Rac1, because both proteins did not co-immunoprecipitate (Fig. 2.5). 
Although one cannot disregard the possibility of a transient interaction 
occurring between the two proteins, these data suggest that BCL-6 rather 
responds to a signalling pathway downstream of Rac1.  
Rac signalling activates the production of ROS via NADPH 
oxidases (Schuringa et al., 2001), and ROS are known to modulate the 
activity of several transcription factors such as AP-1, ETS, Smad, Snail 
and NF-κB (Wu, 2006). However, we demonstrate that Rac1-induced 
production of NADPH oxidases had no effect on BCL-6 activity. 
Overexpression of activated Cdc42 also induced a weak but significant 
stimulation of the BCL-6 reporter, and Cdc42 shares the downstream 
effectors PAK and JNK with Rac1 (Hall, 2005). Because BCL-6 can be 
downregulated by phosphorylation in B cells (Niu et al., 1998; Phan et al., 
2007), we tested the effect of constitutively active kinase mutants on  
BCL-6 activity.  
We found that the activation of PAK was required for the observed 
changes in BCL-6 activity. PAK1 was found to be the predominantly 
expressed PAK isoform in the colorectal cells studied, and its 
overexpression mimics the effect of active Rac1 on nuclear distribution, 
chromatin-binding, or transcriptional activity of BCL-6. Moreover, 
interfering with PAK1 function by siRNA-mediated depletion, cell treatment 
with inhibitor IPA-3, or expression of a dominant-negative PAK1 mutant 
strongly inhibited the effect of Rac1-L61 on the BCL-6 reporter. In all 
these experiments, no detectable changes in the total amount of BCL-6 
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protein were observed. PAK1 could be isolated in a protein complex with 
BCL-6 and was able to phosphorylate BCL-6 in vitro (Fig. 2.9). PAK1 was 
further recruited to the cell nucleus in BCL-6-overexpressing cells and 
colocalized with BCL-6 in the nucleoplasm. Together, these data identify 
PAK1 as the critical mediator between Rac1 activation and BCL-6 
downregulation. 
PAK1 phosphorylation has been found to modulate various 
transcriptional regulators with respect to their transcriptional activity, 
subnuclear location and nuclear import or export (Kumar et al., 2006). Our 
results therefore reveal that the regulation of BCL-6 repressor activity by 
PAK1 constitutes yet another pathway through which this kinase exerts its 
control over specific transcriptional events. In addition, the identification of 
PAK1 as the link between Rac1 and BCL-6 is in agreement with our 
observation that splicing variant Rac1b, which was previously shown 
unable to stimulate PAK1 activation (Matos et al., 2003; Singh et al., 
2004), had no significant effect on the BCL-6 transcriptional reporter 
activity, on the subnuclear localization of BCL-6, and on its transition into 
a soluble nuclear fraction. 
One of the physiological target genes for BCL-6 repression is 
NFKB1 encoding the p105 precursor protein for the NF-κB member p50. 
In response to Rac1 signalling, we found increased levels of p105 
transcripts and of p50 protein, which is generated from p105 via a 
constitutive proteolytic pathway (Karin et al., 2002; Moorthy et al., 2006). 
p50 can dimerize with various Rel partner proteins and the resulting 
protein complexes can either activate or repress transcription (Fujita et al., 
1993; Baer et al., 1998; Zhong et al., 2002; Driessler et al., 2004; 
Wessells et al., 2004; Guan et al., 2005). Therefore, the physiological 
effect of increasing p50 levels in response to Rac1 activation is not readily 
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apparent. We speculate that a short-term effect will be an increased 
availability of transcriptionally competent Rel protein/p50 dimers that make 
any NF-κB stimulation more robust. On a longer term, however, increasing 
p50 levels may favor the formation of p50/p50 homodimers that can act as 
repressors and downregulate the NF-κB response, similar to what has 
been described during the inflammatory response (Baer et al., 1998; 
Driessler et al., 2004). 
Another endogenous BCL-6 target gene that is expressed in colon 
is CD44 (Shaffer et al., 2000). The CD44 family is a family of cell-surface 
glycoproteins involved in cell-matrix adhesion and growth factor 
presentation and was shown to influence cell growth, survival and 
differentiation. Members of the CD44 family have been implicated in the 
progression and metastasis of tumours (Ponta et al., 2003), including 
colorectal tumours (Wielenga et al., 1993; Herrlich et al., 1995; Gotley et 
al., 1996; Ropponen et al., 1998; Wielenga et al., 1999). Our data 
therefore suggest that a deregulation of Rac1 signalling may contribute to 
the altered CD44 expression described in colorectal tumours.  
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3.1. Summary 
 
Gene expression depends on binding of transcriptional regulators 
to gene promoters, a process controlled by signalling pathways. The 
transcriptional repressor BCL-6 downregulates genes involved in          
cell-cycle progression and becomes inactivated following phosphorylation 
by the Rac1 GTPase-activated protein kinase PAK1. Interestingly, the 
DNA motifs recognized by BCL-6 and STAT5 are similar. Because STAT5 
stimulation in epithelial cells can also be triggered by Rac1 signalling, we 
asked whether both factors have opposing roles in transcriptional 
regulation and whether Rac1 signalling may coordinate a transcription 
factor switch. We used chromatin immunoprecipitation to show that active 
Rac1 promotes release of the repressor BCL-6 while increasing binding of 
STAT5 to a BCL-6-regulated reporter gene. We further show in colorectal 
cell lines that the endogenous activation status of the Rac1/PAK1 pathway 
correlated with the phosphorylation status of BCL-6 and STAT5. Three 
cellular genes (cyclin D2, p15INK4B, small ubiquitin-like modifier 1) were 
identified to be inversely regulated by BCL-6 and STAT5 and responded 
to Rac1 signalling with increased expression and corresponding changes 
in promoter occupancy. Together, our data show that Rac1 signalling 
controls a group of target genes that are repressed by BCL-6 and 
activated by STAT5, providing novel insights into the modulation of gene 
transcription by GTPase signalling. 
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3.2. Introduction 
 
A crucial process in gene expression is the initiation of gene 
transcription. Before ribonucleic acid (RNA) polymerase II can transcribe 
the coding information of a given gene into RNA, it generally needs to be 
recruited to the respective gene promoter by specific transcription factors. 
These factors recognize conserved short DNA sequence motifs in the 
promoter but usually only bind to them following transcription factor 
activation and chromatin remodelling. Consequently, transcriptional 
regulation is frequently preceded by cellular signalling events. For 
example, activation of growth factor receptors at the plasma membrane 
stimulates the Ras/RAF/extracellular signal-regulated kinase (ERK) 
pathway, and activated ERK translocates into the nucleus where it 
phosphorylates transcription factors such as ETS-like transcription factor 1  
(ELK-1) and Myc, enabling them to bind and activate target gene 
promoters (Plotnikov et al., 2011). A different strategy is used by activated 
cytokine receptors, which stimulate tyrosine phosphorylation of the signal 
transducers and activators of transcription (STAT) family of transcription 
factors at the plasma membrane and these activated factors then 
translocate into the nucleus to activate their target genes (Horvath, 2000). 
Another signalling molecule activated downstream of membrane 
receptors is the small guanosine triphosphatase (GTPase) Rac1, initially 
discovered for its ability to stimulate the polymerization of actin filaments 
and cell migration (Hall, 1998). In addition, Rac1 has distinct roles in the 
regulation of gene transcription (Benitah et al., 2004). For instance, the 
stimulation of c-Jun N-terminal kinase (JNK) by Rac signalling leads to the 
phosphorylation and subsequent activation of the transcription factors     
c-Jun, ELK, activating transcription factor (ATF) or activator protein 1   
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(AP-1). A further transcription factor stimulated by Rac1 signalling is 
nuclear factor kappa-light-chain-gene-enhancer of activated B cells     
(NF-κB) and involves the phosphorylation and proteolytic degradation of 
the cytoplasmic inhibitor proteins IκBα and NF-κB2/p100 (Boyer et al., 
2004; Matos and Jordan, 2006).  
Some STAT factors were also reported to be regulated by Rac1. 
They form a family of seven transcription factors, are found in the 
cytoplasm under basal conditions and enter the nucleus following their 
activation by tyrosine phosphorylation (Horvath, 2000). STAT3 binds 
directly to active Rac1, possibly targeting STAT3 to tyrosine kinase 
signalling complexes (Simon et al., 2000). In addition, Rac1 and a 
GTPase-activating protein, MgcRacGAP, bind directly to phosphorylated 
STAT3 and STAT5A, promoting their nuclear translocation and activity 
(Tonozuka et al., 2004; Kawashima et al., 2006).  
Previously, we reported a novel link between Rac1 signalling and 
transcriptional regulation. Rac1 activation leads to p21-activated kinase 1 
(PAK1)-mediated phosphorylation of the transcriptional repressor B-cell 
lymphoma (BCL)-6 in colorectal tumour cells and inactivates its repressor 
function (Barros et al., 2009). BCL-6 was initially identified as a repressor 
gene translocated in B-cell non-Hodgkin’s lymphomas (Seyfert et al., 
1996; Staudt et al., 1999; Dent et al., 2002). Later, BCL-6 expression has 
also been detected in non-hematopoietic tissues, including skeletal 
muscle (Bajalica-Lagercrantz et al., 1998), uroepithelial cells (Lin et al., 
2003; Huang et al., 2007), olfactory sensory neurons (Otaki et al., 2005), 
skin (Kanazawa et al., 1997), epithelial cells of the mammary gland 
(Logarajah et al., 2003) and HeLa cells (Allman et al., 1996). BCL-6 
contains carboxy-terminal zinc finger modules that bind DNA in a 
sequence-specific manner (Chang et al., 1996; Huynh et al., 2000). The 
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genes repressed by BCL-6 are best studied in germinal centre B cells and 
are involved in lymphocyte activation and terminal differentiation, including 
cell-cycle regulation (Dalla-Favera et al., 1999; Staudt et al., 1999; Shaffer 
et al., 2000; Niu, 2002).  
Interestingly, the DNA motifs recognized by BCL-6 are highly 
homologous to the core binding sequence TTCNNNGAA of STAT factors 
STAT5 (Dent et al., 1997; Horvath, 2000). This raised the hypothesis that 
both factors may have opposing roles in the transcriptional regulation of 
some target genes. Here, we used chromatin immunoprecipitation (ChIP) 
to show that active Rac1 promotes release of the repressor BCL-6 from 
promoters together with increased binding of STAT5. We also identify 
three endogenous target genes involved in cell-cycle control that were 
inversely regulated by BCL-6 and STAT5 and responded to Rac1 
signalling with a transcription factor switch. 
 
3.3. Material and Methods 
 
3.3.1. Cell culture and transfection 
 
DLD-1 and SW480 colorectal cells were maintained in Dulbecco’s 
minimal essential medium (DMEM) and HT29 cells were kept in Roswell 
Park Memorial Institute (RPMI) medium, both supplemented with         
10% (v/v) foetal bovine serum (FBS) (all reagents from Gibco, Carlsbad, 
CA, USA) and regularly checked for absence of mycoplasm infection. 
Cells were transfected as previously described (Barros et al., 2009) using 
a 1:2 proportion (µg/µl) of DNA:LipofectAMINE 2000 (Invitrogen, Carlsbad, 
CA, USA) and total amounts of transfected plasmid DNA of 12 µg per  
100-mm dish for ChIP assays, 4 µg per 60-mm dish for 
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immunoprecipitation and pull-down assays and 2 µg per 35-mm dish for 
cell fractionation, reporter assays, immunofluorescence and transcript 
expression analysis in case of DLD-1 and SW480 cells, but twice the 
amount for HT29 cells. When required, the amount of DNA was adjusted 
with empty vector. Optimal transfection efficiencies were 60 to 80% in 
DLD-1 or SW480 cells and 40 to 60% in HT29, as judged microscopically 
by expression of green fluorescent protein (GFP)-tagged vector and cells 
analysed 16-20 h later.  
For RNA interference experiments, cells were transfected at 20 to 
40% confluence in 35-mm dishes with either 200 pmol (DLD-1) or         
400 pmol (HT29) of the indicated siRNAs using LipofectAMINE 2000 
(Invitrogen) and analysed 48 h later. The small interfering RNA (siRNA) 
oligos against BCL-6 (sc-29791), STAT5A (sc-29495) and PAK1           
(sc-29700) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
and a scramble control oligonucleotide (5’-AGG UAG UGU AAU CGC 
CUU GTT) from Eurofins MWG Operon (Ebersberg, Germany).  
 
3.3.2. DNA plasmids and constructs  
 
The following published constructs were received as gifts:     
PAK1-wt, kinase-dead dominant-negative PAK1-K299R and constitutively 
active PAK1-T423E mutants from J. Chernoff (Fox Chase Cancer Center, 
Philadelphia, PA, USA), and the 5xBCL-6-vector and the pGL3 control 
vector (Huynh et al., 2000) from V.J. Bardwell (University of Minnesota, 
Minneapolis, MN, USA). Rac1 cDNA and their Q61L and T17N mutants 
were subcloned as an EcoRI/BamHI fragment into pcDNA3-Myc, pEGFP 
(Clontech, Mountain View, CA, USA) and pDsRed-C1 (Clontech) vectors 
as previously described (Matos et al., 2003; Matos and Jordan, 2006; 
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Barros et al., 2009). All pEGFP-PAK1 constructs and pEGFP-BCL-6 were 
previously described (Barros et al., 2009). STrEP-tagged BCL-6 was 
generated by subcloning a BamHI/XhoI fragment from pcDNA3-BCL-6 
into vector pEXPR-IBA105 (IBA, Göttingen, Germany). pEGFP-STAT5A 
was generated by polymerase chain reaction (PCR) amplification of the 
STAT5A cDNA from pMX-STAT5A (gift from B. Groner, University of 
Frankfurt, Germany) using a forward primer (5’-ATG GCG GGC TGG ATT 
CAG G) and a reverse primer (5’-ATC TCA GGA CAG GGA GCT TCT) 
and subcloned into pEGFP-C2 using EcoRI restriction sites. All constructs 
were confirmed by automated DNA sequencing. 
 
3.3.3. Analysis of transcript expression by quantitative reverse 
transcription-PCR  
 
Total RNA was extracted from cell lysates with the NucleoSpin 
RNA kit (Macherey-Nagel, Düren, Germany) and 1 µg reverse transcribed 
using random primers (Invitrogen) and Ready-to-Go You-Prime First-
Strand Beads (GE Healthcare, Buckinghamshire, UK). CCND2, CDKN2B 
and small ubiquitin-like modifier 1 (SUMO1) transcript levels were 
determined by quantitative real-time PCR (qPCR) on an ABI Prism 7000 
Sequence Detection System (Applied Biosystems, Foster City, CA, USA) 
using the primers and PCR conditions summarized in Supplementary 
Table S3.1. Each cDNA sample was diluted 5-fold to guarantee accurate 
pipetting and 5 µl added to each real-time reaction together with 200 nM 
primers and SYBR Green Master Mix (Applied Biosystems). Data were 
analysed with the 7000 SDS 1.1 RQ Software (ΔΔCT method, Applied 
Biosystems) (Matos et al., 2008) using mock transfections as reference 
samples. For comparison of gene expression between cell lines a pool of 
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cDNAs mixed at equal parts from the three cell lines was used as 
reference. 
Semi-quantitative reverse transcription PCR (RT-PCR) was used 
to estimate siRNA-mediated knockdown of BCL-6 and STAT5A 
expression. RNA polymerase II (as earlier; Pol II) was amplified as a 
control gene and two serial dilutions of scramble siRNA sample served to 
assure semi-quantitative PCR conditions and estimate knockdown 
efficiency.  
 
3.3.4. PCR array analysis  
 
The Human Cell-Cycle PCR array (PAHS-020, Qiagen, Hilden, 
Germany) was used according to manufacturer’s instructions. An RNA 
pool from three independent siRNA experiments performed in DLD-1 or 
HT29 cells was reverse transcribed, then added to a SYBR Green/Rox 
qPCR Master Mix (PA-012, Qiagen), distributed into the 96-well array 
plate and measured by qPCR as described above. The quantitative 
analysis was done on an ABI Prism 7000 Sequence Detection System 
(Applied Biosystems) with the following cycling conditions: 10 min at 95ºC 
and 40 cycles at 95ºC for 15 s and 60ºC for 60 s. Two PCR arrays were 
used for each experimental condition. Data analysis was performed using 
the Excel-based tool provided by the manufacturer. 
 
3.3.5. Identification of putative BCL-6/STAT5 binding sites  
 
A 2500 bp of the genomic sequence immediately upstream the 
annotated transcription initiation sites for CCND2, CDKN2B and SUMO1 
genes were used to search in silico for putative binding sites recognized 
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simultaneously by BCL-6 and STAT5A. Several algorithms were 
employed (http://www.gene-regulation.com/; http://www.biobase-
international.com/;	   http://www.genomatix.de) using the score values 
obtained for the previously described BCL-6/STAT5 site in CCND2 
(Fernández de Mattos et al., 2004) as a reference for parameter 
adjustment and best putative site selection.  
 
3.3.6. Chromatin immunoprecipitation (ChIP)  
 
When indicated, DLD-1, SW480 or HT29 cells were transfected 
with expression vectors and assayed 16 h later. ChIP was performed as 
previously described (Fernández de Mattos et al., 2004). Briefly, 
approximately 10 x 106 cells per ChIP were cross-linked with                  
1% formaldehyde for 10 min at 37ºC, washed twice in cold phosphate-
buffered saline (PBS), scraped off and lysed sequentially in Buffer I 
(0.25% [v/v] Triton X-100, 10 mM EDTA, 0.5 mM EGTA, 10 mM HEPES-
KOH [pH 6.5]), Buffer II (200 mM NaCl, 10 mM EDTA, 0.5 mM EGTA,    
10 mM HEPES-KOH [pH 6.5]) and finally ressuspended in Sonication 
buffer (50 mM Tris-HCl [pH 8.1], 5 mM EDTA, 150 mM NaCl, 0.5% [v/v] 
Triton X-100, 0.5% [v/v] SDS), all supplemented with a protease inhibitor 
cocktail (Sigma, St. Louis, MO, USA). Lysates were then sonicated to 
obtain chromatin fragments between 200 and 500 bp length (40% power 
on a Sonics Vibra Cell sonicator). Cleared samples were diluted 5 times 
with Buffer D (50 mM Tris-HCl [pH 8.1], 5 mM EDTA, 150 mM NaCl,   
0.5% [v/v] Triton X-100, protease inhibitor cocktail [Sigma]) and incubated 
overnight at 4ºC with either anti-BCL-6 clone N3 (sc-858; Santa Cruz 
Biotechnology), anti-STAT5A (#13-3600; Invitrogen) or control anti-rabbit 
immunoglobulin G (IgG) (P0448; DakoCytomation, Glostrup, Denmark) 
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antibodies, preserving 1/10 lysate volume as input control. Protein G-
conjugated magnetic beads (Invitrogen) were then added for 1 h at 4ºC. 
Beads were thoroughly washed with Wash buffer (20 mM Tris-HCl        
[pH 8.1], 150 mM NaCl [pH 8.1], 2 mM EDTA, 1% [v/v] Triton-X-100,  
0.1% [v/v] SDS) and with TE (10 mM Tris-HCl [pH 8.0], 1 mM EDTA 
[pH8.0]). Co-precipitated DNA was extracted with 1% [v/v] SDS and              
0.1 M NaHCO3 solution and purified with the QIAquick PCR purification kit 
(Qiagen) after cross-link reversion. Input control samples were subjected 
to the same treatment. The selected putative STAT5A/BCL-6 binding 
regions were amplified from ChIP samples with the primers and conditions 
described in Supplementary Table S3.1. As a specificity control, a 
genomic fragment between intron 8 and intron 10 of the MutY homolog 
(MUTYH) gene (Accession number NG_008189) was amplified. Products 
were separated on 2% agarose gels containing ethidium bromide. Two 
serial dilutions of the “input DNA” control were co-amplified to guarantee 
semi-quantitative PCR conditions and allow product quantity extrapolation 
from band intensities analysed on digital images using ImageJ software 
(National Institutes of Health – NIH), which were then normalized to the 
control sample. 
 
3.3.7. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blotting 
 
Samples were prepared and detected as described (Matos et al., 
2003; Barros et al., 2009). The antibodies used for Western blots were as 
follows: polyclonals anti-c-Myc clone A14 (sc-789), anti-Histone H2B    
(sc-10808) and anti-BCL-6 clone N3 (sc-858) from Santa Cruz 
Biotechnology; monoclonal anti-GFP from Roche (#11814460001; 
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Penzberg, Germany); monoclonal anti-PAK1 from Abcam (ab40795; 
Cambridge, UK); monoclonal anti-Rac1 clone 23A8 from Upstate 
Biotechnologies (#05-389; Charlottesville, Virginia, USA); polyclonals anti-
phospho-PAK1 (Ser199/204)/PAK2 (Ser192/197) (#2605) and anti-
phospho-STAT5A (Tyr694) (#9351) from Cell Signalling Technology 
(Danvers, MA, USA); monoclonal anti-STAT5A from Invitrogen (#13-3600) 
and monoclonal anti-α-tubulin clone B-5-1-2 (as loading control; T6074) 
from Sigma. For densitometric analysis, films from at least three 
independent experiments were digitalized and analysed using ImageJ 
software (NIH). 
 
3.3.8. Active Rac pull-down assays and immunoprecipitation  
 
 Approximately 2 x 106 DLD-1 cells were seeded in 60-mm dishes, 
transfected as indicated, and assayed 16 to 20 h later. Cells were washed 
in cold PBS and lysed on ice in 250 µl of non-denaturing lysis buffer      
(50 mM Tris-HCl [pH 7.5], 100 mM NaCl, 1% [v/v] Nonidet P-40 (NP-40), 
10% [v/v] glycerol, 5 mM MgCl2, and a protease inhibitor cocktail [Sigma]). 
For Rac pull down assay, total lysates were cleared by centrifugation at 
2,500 x g for 5 min and 0.1 volume was added to 5x Laemmli sample 
buffer. The remaining lysate was incubated for 1 h at 4°C with a 
biotinylated CRIB-domain peptide pre-coupled to streptavidin-agarose 
beads (Sigma) as previously described (Matos and Jordan, 2006). Beads 
were washed three times with excess lysis buffer and the precipitated 
protein complexes were solubilised in 2x Laemmli sample buffer. Total 
lysates and precipitates were then analysed by Western blot as described 
above. The co-immunoprecipitation procedure (Barros et al., 2009) was 
identical, with exception that total lysates were sonicated on ice (10 pulses 
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of 20 s at 40% power on a Sonics Vibra Cell sonicator) before incubation 
with streptavidin-agarose beads (Sigma), that were washed five times with 
an excess of lysis buffer containing 300 mM of NaCl. Precipitates and 
sonicated lysates were also analysed by Western blot. 
All results were confirmed in at least three independent 
experiments.  
 
3.3.9. Cell fractionation 
 
Proteins were separated into a soluble pool not retained in the 
nucleus and into a chromatin-bound insoluble pool according to previously 
described procedures (Solan et al., 2002; Barros et al., 2009). Briefly, 
cells were washed in cold PBS, scraped off and lysed on ice in 
fractionation buffer (50 mM Tris-HCl [pH 7.9], 0.1% [v/v] NP40,                
1.5 mM MgCl2, 10 mM KCl and a protease inhibitor cocktail [Sigma]). The 
soluble fraction was collected by centrifugation and adding the 
supernatant to 5x Laemmli sample buffer. The pellet containing the 
insoluble nuclear fraction was washed once in fractionation buffer and 
then resuspended in 1x Laemmli sample buffer supplemented with           
5 mM MgCl2 and 50 U endonuclease (Benzonase, Sigma) to digest 
nucleic acids. Equal volumes of both fractions were analysed side by side 
on Western blots. Results were confirmed in at least three independent 
experiments. 
 
3.3.10. Luciferase reporter assay 
 
The use of the pGL3-5xBCL-6 reporter vector in DLD-1 cells was 
previously described (Barros et al., 2009). Briefly, cells were co-
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transfected with pRL-TK luciferase reporter (internal control; Promega, 
Fitchburg, WI, USA), pGL3-5xBCL-6 or pGL3 control reporters, and the 
indicated expression constructs. After 16 to 20 h cells were lysed and 
assayed with the Dual Luciferase Reporter Assay (Promega) and 
measured in an Anthos Lucy-2 Luminometer. Lysates were assayed in 
duplicates and additional aliquots analysed by Western Blot to document 
protein expression levels. Normalized luciferase values were plotted as 
fold-increase over the value of control treatments and correspond to at 
least three independent transfection assays.  
 
3.3.11. Confocal immunofluorescence microscopy  
 
Experiments were performed as previously described (Barros et 
al., 2009). Cells were grown on glass cover slips (10 by 10 mm), 
transfected and incubated as indicated above, then washed twice in PBS, 
immediately fixed with 4% (v/v) formaldehyde in PBS for 30 min at room 
temperature, and subsequently permeabilized with 0.2% (v/v) Triton X-100 
in PBS for 10 min at room temperature. Cells were then briefly stained 
with 0.5 ng/ml 4',6-diamidino-2-phenylindole (DAPI) (Sigma) and washed 
in PBS, and the cover slips mounted in VectaShield (Vector Laboratories, 
Burlingame, CA, USA) and sealed with nail polish. Images were recorded 
with a Leica TCS-SPE confocal microscope and processed with Leica and 
Adobe Photoshop software.  
 
3.3.12. Statistical analysis 
 
Statistical significance of the differences between treated and 
control samples was analysed using two tailed Student’s t-tests and 
indicated in the figures by an asterisk (*) whenever p< 0.05. 
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3.4. Results 
 
3.4.1. Rac1 signalling promotes transcription by repressing BCL-6 
and stimulating STAT5 
 
Recently, we used a BCL-6 reporter gene construct (Fig. 3.1A) in 
which five repeats of a BCL-6 recognition motif control luciferase 
expression and found that Rac1 signalling acts as an upstream regulator 
of BCL-6 in colorectal DLD-1 cells (Barros et al., 2009). When this reporter 
was transfected into DLD-1 cells together with GFP-tagged BCL-6, a 
further repression was observed, whereas depletion of endogenous   
BCL-6 expression by RNA interference led to transcriptional activation 
(Fig. 3.1B). In the course of these studies, we noticed that the expression 
of active Rac1-L61 had a stronger stimulatory effect on reporter gene 
transcription than a constitutively active PAK1-T423E mutant (Fig. 3.1B), 
although PAK1 is activated downstream of Rac1 and was shown to 
phosphorylate BCL-6 (Barros et al., 2009). We thus reasoned that Rac1 
may activate additional PAK1-independent pathways that affect reporter 
gene activation. One candidate pathway was activation of STAT5 because 
STAT5 was reported to recognize BCL-6 binding motifs in some cellular 
genes, including cyclin D2 or prolactin (Shaffer et al., 2000; Tang et al., 
2002; Fernández de Mattos et al., 2004; Meyer et al., 2009; Tran et al., 
2010), and because it formed a complex with active Rac1 promoting 
STAT5 nuclear import and transcriptional activation (Kawashima et al., 
2006).         
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Figure 3.1. Rac1 signalling promotes transcription by repressing BCL-6 and 
stimulating STAT5. (A) Schematic representation of the transcriptional luciferase 
reporter vector under the control of five consensus BCL-6 binding motifs. (B) 
DLD-1 cells were co-transfected with the reporter vector and the indicated 
expression vectors or siRNAs. Cells were lysed 24 h later and luciferase activity 
was measured and graphically displayed, *P<0.05. The Western blot below the 
graph shows the levels of transfected GFP-tagged BCL-6, Rac1-L61, PAK1 
kinase-dead (kd) or PAK1 constitutively active (ca) mutants. Detection of 
endogenous α-tubulin served as loading control. The small insert beside the 
graph shows a Western blot of endogenous BCL-6 to document the efficiency of 
its siRNA-mediated depletion.   
Chapter 3
 
	  132 
 To test whether active Rac1 could promote nuclear translocation of 
STAT5 in DLD-1 cells, we first applied a cell fractionation protocol, which 
separates transcription factors into a soluble pool that is extracted from 
the nucleus and a chromatin-bound pool that remains insoluble (Barros et 
al., 2009). Under control conditions, STAT5 was detected in the soluble 
fraction (Fig. 3.2A), whereas in cells co-expressing an active Rac1-L61 
mutant a notable transition of STAT5 into the chromatin-bound insoluble 
fraction was observed (Fig. 3.2A). Second, we visualised the effect of 
active Rac1 on STAT5 by fluorescence microscopy in cells co-transfected 
with DsRed-Rac1-L61 and GFP-STAT5A. As shown in Figure 3.2B, a 
clear transition of STAT5 into the nucleus was observed. 
To confirm whether STAT5 was able to activate the BCL-6 reporter 
gene under these conditions, both constructs were co-transfected into 
DLD-1 cells and increased luciferase transcription was measured (Fig. 
3.3A). We then co-expressed STAT5 and constitutively active PAK1 to 
test whether their combined transcriptional activation would mimic that 
induced by Rac1-L61. As shown in Figure 3.3A, simultaneous stimulation 
of PAK1 and STAT5 could indeed account for the complete stimulatory 
effect induced by Rac1 signalling.  
 
3.4.2. Rac1 signalling switches promoter occupancy from BCL-6 to 
STAT5 
 
These results suggested that Rac1 signalling activates two 
independent pathways of transcriptional regulation that target the same 
reporter gene. To obtain further support for this conclusion, we determined 
the occupancy of the reporter gene promoter by either BCL-6 or STAT5 
under  the  various  experimental  conditions. For  this,  DLD-1  cells  were      
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Figure 3.2. Rac1 signalling affects chromatin binding and subnuclear 
location of STAT5. (A) DLD-1 cells were transfected with Myc-Rac1-L61 or control 
empty vector and 24 h later analysed by Western blot for the subcellular distribution 
of STAT5 between a soluble (S) and a chromatin-bound non-soluble (NS) fraction 
(detection of α-tubulin and histone H2B served as controls). Note that active Rac1 
promotes retention of STAT5 in the non-soluble chromatin fraction. (B) Subcellular 
localization of STAT5 determined by confocal fluorescence microscopy in DLD-1 
cells co-transfected with DsRed-Rac1-L61 and GFP-STAT5A. The overlay image of 
the DAPI, GFP and DsRed channels is shown. A microscopic field was chosen that 
contained side by side untransfected cells (blue nuclei), cells that transfected only 
with GFP-STAT5A (green cells) and cells that co-transfected with both              
GFP-STAT5A and DsRed-Rac1-L61 (red cells). Note the nuclear STAT5 signal in 
Rac1-expressing red cells. In addition, two plots are given showing the DAPI and 
GFP signal intensities measured along the indicated regions of interest (ROI, white 
lines). The signal intensity of GFP did not increase across the nuclear DAPI region 
when cells expressed only GFP-STAT5A (green cells, ROI 1), whereas nuclear 
GFP signal clearly increased when cells co-expressed active Rac1 (red cells,     
ROI 2), confirming nuclear translocation of GFP-STAT5A. 
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co-transfected with the BCL-6 reporter gene and either control vector or 
active Rac1-L61 or active PAK1-T423E and the presence of either 
transcription factor at the reporter gene promoter was analysed by ChIP. 
As shown in Figure 3.3B, BCL-6 was the predominantly bound factor in 
control cells, however, upon expression of active Rac1 BCL-6 binding was 
reduced and STAT5 became the predominantly bound factor at the 
promoter. To exclude that the observed changes in promoter occupancy 
were the result of epitope masking (due to an interaction of BCL-6 and 
STAT5 at the promoter that could interfere with recognition by their 
specific ChIP antibodies), co-precipitation studies were carried out 
(Supplementary Fig. S3.1). No evidence was found for complex formation 
between the two transcription factors, indicating that changes in promoter 
occupancy reflected changes in bound proteins. In case of active PAK1, 
BCL-6 was also partially reduced, and this is in agreement with our 
previous data that PAK1 phosphorylates BCL-6 and promotes its release 
from chromatin and loss of repressor activity. However, in contrast to 
active Rac1, PAK1 was unable to invert the promoter occupancy from 
BCL-6 to STAT5. Together, these data support the conclusion that Rac1 
signalling activates two independent pathways to promote a switch in 
promoter occupancy from BCL-6 to STAT5.  
 
3.4.3. Correlation of Rac1 signalling and activation of BCL-6 or 
STAT5 in different cell lines 
 
 To understand the physiological relevance of the observed 
transcriptional switching at the reporter gene, we first characterized the 
endogenous activity levels of Rac1, PAK1, STAT5 and BCL-6 in three 
different  colorectal  cell  lines  using  Western blot  analysis. As  shown  in  
Rac1 modulates a BCL-6/STAT5 transcriptional switch
 
 
	   135 
 
Figure 3.3. Rac1 signalling switches promoter occupancy from BCL-6 to 
STAT5A. (A) DLD-1 cells were co-transfected with the reporter and the indicated 
expression vectors, as described for Figure 3.1B. Note that STAT5 activates the 
BCL-6 luciferase reporter and, when combined with PAK1, reaches the 
stimulation levels normally induced by active Rac1, *P<0.05 and #P>0.05. (B) 
ChIP of the reporter vector with anti (α-)-BCL-6, α-STAT5 or a non-specific 
antibody (Ns IgG) from lysates of DLD-1 cells transfected with the indicated 
expression vectors. A representative semi-quantitative PCR of the precipitated 
promoter fragment quantities with a graphical representation of the respective 
band intensities quantified by densitometry from digital images obtained in three 
independent transfection experiments, *P<0.05, is shown. Two serial dilutions of 
input DNA were co-amplified to guarantee semi-quantitative PCR conditions and 
allow product quantity extrapolation from band intensities. 
 
Figure 3.4, SW480 cells revealed the strongest endogenous Rac1 
activation level, followed by HT29 and DLD-1 cells. Curiously, SW480 cell 
lost PAK1 expression, whereas in HT29 and DLD-1 cells, active Rac1 was 
proportional to active PAK1, as well as to the levels of phospho-BCL-6 
and phospho-STAT5. Interestingly, SW480 cells expressed BCL-6 as well 
as STAT5 but lacked any significant activation by phosphorylation. This 
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suggested that repression by BCL-6 should be predominant in these cells, 
indicating their usefulness as a negative control for the transcriptional 
switch to STAT5 in subsequent experiments. 
 
Figure 3.4. Correlation of Rac1 signalling and activation of PAK1, BCL-6 or 
STAT5 in different cell lines. Equivalent lysate quantities of DLD-1, SW480 and 
HT29 colorectal cells were separated by gel electrophoresis and analysed by 
Western blot using the indicated antibodies to compare protein levels. The active 
Rac1 fraction was obtained by CRIB-pull down assays, as described (Matos and 
Jordan, 2006). 
 
3.4.4. Identification of endogenous genes inversely regulated by 
BCL-6 and STAT5 
 
As a next step to identify physiological targets of the observed 
transcriptional switching, an array of 84 cell-cycle-related genes was 
tested for opposite effects of BCL-6 and STAT5 on gene expression. For 
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this, the two cell lines that showed endogenous BCL-6 and STAT5 
activation, DLD-1 and HT29, were independently transfected with siRNAs 
targeting either BCL-6 or STAT5 (Supplementary Fig. S3.2). qPCR 
analysis of the resulting gene expression levels identified three genes that 
were affected in opposite sense by the downregulation of either BCL-6 or 
STAT5, namely cyclin D2 (CCND2), cyclin-dependent kinase inhibitor 
p15INK4B (CDKN2B) and small ubiquitin-like modifier 1 (SUMO1)           
(Fig. 3.5A).  
To determine the respective promoter occupancies in these three 
genes, overlapping binding motifs for BCL-6 and STAT5 were identified 
using a Transfac® database-based algorithm (see Methods section and 
Fig. 3.5B) and used to design ChIP experiments in the three 
aforementioned cell lines. It was found that both factors were bound to the 
three identified promoters regions, albeit to different extent; however, not 
to a control genomic fragment. In SW480 cells (that express no PAK1 and 
have little phospho-BCL-6; Fig. 3.4) the predominant factor that was 
bound to all three promoters was BCL-6, whereas STAT5 was close to 
background levels (Fig. 3.6A, grey bars). In contrast, HT29 cells contained 
more STAT5 bound to these promoters than BCL-6 (Fig. 3.6A, white 
bars), in agreement with their higher endogenous levels of active PAK1, 
phospho-BCL-6 and phospho-STAT5 (cf. Fig. 3.4). In DLD-1 cells        
(Fig. 3.6A, black bars) comparable promoter binding levels were detected 
for both factors (except for the CCND2 promoter that had more BCL-6 
bound). Again, this is in good agreement with the observation described in 
Figure 3.4 that endogenous levels of active PAK1, phospho-BCL-6 and 
phospho-STAT5 in DLD-1 were lower than in HT29 but higher than in 
SW480 cells.   
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Figure 3.5. Identification of endogenous genes inversely regulated by BCL-6 
and STAT5. (A) DLD-1 and HT29 cells were transfected with either BCL-6 or 
STAT5-specific siRNA oligonucleotides and lysed following 48 h for RNA 
extraction (Supplementary Fig. S3.2). A heat map display of the gene expression 
analysis of a cell-cycle PCR array probed with RNA samples obtained from BCL-6 
or STAT5-depleted DLD-1 and HT29 cells, is shown. Of the 84 genes on the 
array, three were identified to be regulated by BCL-6 and STAT5 in opposite 
sense (white boxes). (B) Schematic representation of the promoter regions of the 
three endogenous genes inversely regulated by BCL-6 and STAT5 showing the 
selected best putative motifs, with equivalent predicted binding scores for both 
factors. 
 
 Next, these data on the promoter occupancies of the CCND2, 
CDKN2B and SUMO1 genes were matched to the corresponding gene 
expression levels, validated by qPCR using independently designed PCR 
primers (Fig. 3.6B).  HT29 cells that had less BCL-6 repressor bound than  
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Figure 3.6. Regulation of expression of the CCND2, CDKN2B and SUMO1 
genes. (A) Promoter occupancies with BCL-6 and STAT5 at the CCND2, 
CDKN2B and SUMO1 gene promoters was determined by ChIP with the 
indicated antibodies using lysates of the three indicated cell lines (see legend to 
Fig. 3.3B for details). A representative semi-qPCR of the precipitated promoter 
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fragments and a graphical representation of the respective band intensities, 
*P<0.05, are shown. A control genomic fragment from the MUTYH gene was 
amplified to confirm the specificity of the precipitated target gene promoters. Note 
that BCL-6 binds predominantly in the PAK1-lacking SW480 cells and whereas a 
switch to STAT5 occurs in HT29 cells with active Rac1/PAK1 signalling. (B) Gene 
expression data corresponding to the ChIP analysis of the three genes in the 
three cell lines. Left panel shows representative semi-quantitative RT-PCRs, 
whereas graph at the right shows the result of qPCR analysis of cDNAs collected 
from the three cell lines at three different splitting times. Genes encoding RNA 
polymerase II (Pol II) and the glycolytic enzyme phosphoglycerate kinase 1 
(PGK1) were amplified as control housekeeping genes and a pool of cDNAs 
mixed at equal parts from the three cell lines was used as reference for qPCR. 
Serial dilutions served to assure semi-quantitative conditions in the conventional 
RT-PCR reactions. 
 
DLD-1 cells also revealed higher expression levels for all three genes. 
Surprisingly, SW480 cells also expressed all three genes considerably, 
although BCL-6 was predominantly bound in these cells, indicating they 
use different mechanisms to activate these cell-cycle regulating genes. 
 
3.4.5. Rac1 signalling controls reciprocal roles of BCL-6 and STAT5 
in target gene expression 
 
As final evidence that the transcription factor switch is 
physiologically meaningful, the promoter occupancies at the three genes 
were determined and compared with changes in their respective 
expression levels following activation or inhibition of Rac1 signalling in the 
three different cell lines. For this, cells were transfected with vectors 
encoding either dominant-negative or wild-type PAK1, or dominant-
negative or active Rac1, or with siRNA oligonucleotides directed against 
endogenous PAK1 (depletion documented in Fig. S3.2B). The three 
genes revealed equivalent results, which are represented in Figure 3.7 for 
the SUMO1 gene by displaying the levels of promoter-bound BCL-6        
or   STAT5  alongside  the  respective  target  gene  transcript  levels  and  
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Figure 3.7. Rac1 signalling controls target gene expression by inverting 
promoter occupancy with either BCL-6 or STAT5. The representative analysis 
of the SUMO1 gene is shown in the indicated three colorectal cell lines following 
their transfection with constructs that either activate or inhibit Rac1 signalling. Top 
panels show the graphical display of promoter occupancy by ChIP using either 
anti-BCL-6 (black columns) or anti-STAT5 (white columns) and middle panels the 
respective gene expression levels (grey columns) (see legend to Fig. 3.6 for 
further details), *P<0.05. Bottom panels show Western blot analysis of the cell 
lysates demonstrating the expression levels of the transfected GFP, GFP-Rac1 or 
GFP-PAK1 constructs, as well as the resulting phosphorylation status of 
endogenous STAT5. Note that in SW480, which lack endogenous PAK1, 
depletion of endogenous PAK1 by siRNAs transfection (documented in Fig. 
S3.2B) or expression of dominant-negative PAK1 has no effect on promoter-
bound BCL-6, whereas re-expression of PAK1 leads to loss of BCL-6 from the 
SUMO1 promoter and an increase in gene expression. In the other two cell lines, 
inhibition of Rac1 or PAK1 are clearly correlated with more BCL-6 bound and less 
gene expression, while activation of Rac1 or PAK1 promoted STAT5 binding to 
the promoters and increased transcription.   
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protein expression levels.  Comparable data for the CCND2 and CDKN2B 
genes are shown in Figure 3.8. When PAK1 was transfected into SW480 
cells, which lack endogenous PAK1, a loss of BCL-6 from the promoter of 
all three genes was induced (Fig. 3.7, top panel; Fig. 3.8, top panels), 
which slightly increased their expression levels. By contrast, the depletion 
of endogenous PAK1 had no effect on promoter occupancy or gene 
expression (Fig. 3.7, middle panel; Fig. 3.8, bottom panels), a result in 
agreement with the fact that no endogenous PAK1 is expressed in SW480 
cells. When SW480 cells were transfected with active Rac1, a small 
increase in STAT5 phosphorylation and binding to the promoter was 
observed, however, the overall effect on gene expression was negligible 
because the lack of PAK1 compromised BCL-6 removal from the 
promoter. These data confirm our previous assumption that SW480 cells 
represent a negative control and cannot respond to Rac1 signalling with 
the transcriptional switch between BCL-6 and STAT5. 
In contrast, HT29 and DLD-1 cells both switched BCL-6 and 
STAT5 at the three gene promoters upon transfection with active Rac1 
(Fig. 3.7, top panel; Fig. 3.8, top panels), accompanied by a clear increase 
in STAT5 phosphorylation (Fig. 3.7, bottom panel) and in gene expression 
(Fig. 3.7, middle panel; Fig. 3.8, bottom panels). Upon transfection of 
these cells with PAK1, BCL-6 was lost from the three gene promoters and 
expression increased slightly, however, no significant increase in STAT5 
phosphorylation occurred. In the presence of PAK1-specific siRNAs (as 
well as a dominant-negative PAK1 mutant), BCL-6 promoter occupancy 
increased and expression of the three genes was inhibited.   
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Figure 3.8. Rac1 signalling controls CCND2 and CDKN2B gene expression 
by inverting promoter occupancy with either BCL-6 or STAT5. The 
representative analysis of the CCND2 (A) and CDKN2B (B) genes is shown in the 
indicated three colorectal cell lines following their transfection with constructs that 
either activate or inhibit Rac1 signalling. (A and B) Top panels show the graphical 
display of promoter occupancy by ChIP using either anti-BCL-6 (black columns) 
or anti-STAT5 (white columns) and bottom panels the respective gene expression 
levels (grey columns), *P<0.05 (see legend to Fig. 3.7 for further details).  
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   Altogether, these data provide evidence for the model proposed in 
Figure 3.9, showing that Rac1 signalling has a dual effect on 
transcriptional regulation of the CCND2, CDKN2B and SUMO1 genes.  
 
 
Figure 3.9. Proposed model for the role of Rac1 signalling in the observed 
transcriptional switch. On receptor activation, guanine nucleotide exchange 
factors (GEF) promote GTP binding of Rac1 that stimulates two independent 
pathways. Active Rac1 binds and activates protein kinase PAK1 that migrates into 
the nucleus and phosphorylates chromatin-bound BCL-6, leading to its 
inactivation and loss of promoter occupancy. In parallel, a protein complex is 
formed between active Rac1, MgcRacGAP and STAT5, promoting 
phosphorylation by a tyrosine kinase (TK) and translocation into the nucleus. 
Here, MgcRacGAP stimulates GTP hydrolysis by Rac1 and phospho-STAT5 is 
released and activates gene transcription following binding to the vacant promoter 
sites previously repressed by BCL-6.   
Rac1 modulates a BCL-6/STAT5 transcriptional switch
 
 
	   145 
First, Rac1 activates PAK1 that phosphorylates BCL-6 leading to its 
removal from the target gene promoter and a concomitant increase in 
gene expression. In parallel, Rac1 activates phosphorylation and nuclear 
translocation of STAT5, which binds to the same sequence motif in the 
gene promoter that is recognized by BCL-6 and further increases gene 
expression.  
 
3.5. Discussion 
 
The main finding in this work is that Rac1 signalling activates gene 
transcription by inducing a switch from repressor BCL-6 to activator 
STAT5 at the promoter of certain cellular target genes in colorectal cells.  
 Although BCL-6 is best known as a regulator of B lymphocyte 
growth and differentiation, it is also expressed in epithelial tissues 
including skin (Kanazawa et al., 1997), the mammary gland (Logarajah et 
al., 2003), HeLa cells (Allman et al., 1996) and colorectal cells (Barros et 
al., 2009). Similarly, STATs were described as integral parts of cytokine 
signalling pathways in hematopoietic cells (Horvath, 2000), but meanwhile 
their role in epithelial cancers has been well documented (Calò et al., 
2003). In particular, aberrant activation of STAT5 was found in prostate (Li 
et al., 2005) and colorectal cancer (Xiong et al., 2009). In these cases, the 
activation of STAT5 can be mediated by Rac1 signalling, either through 
the production of reactive oxygen species downstream of  G protein-
coupled receptor (GPCR) stimulation, leading to activation of the tyrosine 
kinase JAK (Pelletier et al., 2003) and/or through complex formation with 
MgcRacGAP promoting nuclear import of phospho-STAT5 (Kawashima et 
al., 2006). Indeed, our study in the colorectal cell lines confirmed that 
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activated Rac1 led to increased phosphorylation of STAT5 (Fig. 3.7) and 
an increase in chromatin-bound nuclear STAT5 (Fig. 3.2A).  
Previous reports have suggested that STAT5 and BCL-6 could 
bind in a mutually exclusive manner to the same sequence motif in the 
promoters of certain target genes (Shaffer et al., 2000; Tang et al., 2002; 
Fernández de Mattos et al., 2004; Meyer et al., 2009; Tran et al., 2010). 
Our data clearly support these studies and show, side by side, that the 
switch in promoter occupancy between BCL-6 and STAT5 correlates 
directly with changes in gene expression of either a BCL-6-controlled 
luciferase reporter vector or of three endogenous gene promoters. More 
importantly, we show for the first time that this switch is regulated by Rac1 
signalling and occurs in colorectal tumour cells. Several pieces of 
evidence contributed to these data. First, ChIP assays revealed that   
BCL-6 and STAT5 were bound to the identified gene promoters in the 
three colorectal cell lines. Second, the endogenous activation status of 
Rac1, PAK1, and phosphorylated BCL-6 or STAT5 correlated well with 
promoter occupancies in the cell lines, without detectable changes in the 
total amount of STAT5 or BCL-6 proteins. Third, experimental activation of 
Rac1 promoted STAT5 phosphorylation and accumulation in the 
chromatin-bound nuclear fraction. Fourth, the transcript expression levels 
of the three endogenous genes mirrored their promoter occupancies and 
responded to activation or inhibition of upstream Rac1 or PAK1 signalling. 
As described earlier, the three colorectal cell lines studied differed 
in their endogenous activation levels of Rac1 signalling and the resulting 
inhibition of BCL-6 or stimulation of STAT5. SW480 cells apparently lost 
PAK1 expression and therefore are unable to phosphorylate BCL-6, 
except when transfected with ectopic PAK1 (Fig. 3.7 and Fig. 3.8). 
Unexpectedly, these cells still revealed significant expression of the 
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CCND2, CDKN2B and SUMO1 genes, which we identified as inversely 
regulated target genes for BCL-6 and STAT5. This experimental 
observation indicates that other mechanisms for transcriptional activation 
of CCND2, CDKN2B and SUMO1 exist and were used by these cells. 
Because the control of gene expression involves combinatorial patterns of 
transcription factor binding, the inhibitory effect of BCL-6 was most likely 
overcome in SW480 cells by other transcription factors that respond to 
different signalling inputs. For example, the ability of Myc to induced 
CCND2 as well as CDKN2B expression has been reported (Bouchard et 
al., 1999; Staller et al., 2001) and SW480 cells carry an oncogenic 
mutation in the KRAS gene (Matos et al., 2008), a strong activator of 
several signalling pathways. 
In contrast, HT29 and DLD-1 cells shared the same regulatory 
pattern of BCL-6 inhibition and STAT5 activation, differing only in the 
extent of BCL-6 inhibition, which was more pronounced in HT29 cells. 
However, on transfection of active Rac1 or PAK1 mutants, the resulting 
transcriptional stimulation became almost identical in both cell lines. The 
same was true for the strong inhibitory effect after depletion of 
endogenous PAK1 by RNA interference or transfection of a dominant-
negative PAK1 mutant, whereas SW480 cells did not respond to either 
treatment. Together, these data provide substantial evidence that Rac1 
signalling promotes a switch at the targeted promoters with a release of 
BCL-6 and enhanced binding of STAT5 to the same site. 
Of the 84 cell-cycle related genes analysed, three (3.6%) were 
clearly identified as inversely regulated by BCL-6 and STAT5. CCND2 
encodes cyclin D2, which functions as a regulatory subunit of CDK4 or 
CDK6 required for cell-cycle G1/S transition. CCND2 overexpression has 
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been reported in colorectal tumours and cell lines (Mermelshtein et al., 
2005; Liu et al., 2010). 
The SUMO1 gene encodes a small ubiquitin-like protein that can 
be covalently attached to proteins as a monomer or a lysine-linked 
polymer. Unlike ubiquitin, sumoylation is not involved in proteolytic 
degradation of the attached protein but rather modulates nuclear transport 
or transcriptional regulation (Gareau and Lima, 2010). 
CDKN2B encodes the cyclin-dependent protein kinase inhibitor 
protein p15 encoded by the INK4b locus, which can form a complex with 
CDK4 or CDK6, and prevent their activation by cyclin D. Although CCND2 
and SUMO1 overexpression are consistent with the pro-proliferative role 
usually associated with increased Rac1 signalling, the role of CDKN2B 
during colorectal cancer progression remains unclear. Intriguingly, the 
expression of p15 was also found significantly increased in higher grade 
prostate carcinomas (Zhang et al., 2006), indicating that alternative 
mechanisms may exist to inactivate its inhibitor function. 
Although the particular functional consequences require further 
clarification, our findings provide a mechanistic model for how Rac1 
signalling promotes switching between transcription factors (see Fig. 3.9). 
Beyond the rapid regulation by Rac1 signalling, the described interplay 
between STAT5 and BCL-6 is likely also modulated at the long term 
because STAT5 was found to act as a transcriptional repressor on the 
BCL-6 gene itself (Walker et al., 2007). In addition, STAT5 has been 
described to act as a transcriptional repressor on other genes (Luo and 
Yu-Lee, 1997; Nelson et al., 2004). This underlines the requirement for a 
genome-wide study to understand which genes are activated or repressed 
by BCL-6 or STAT5 alone, and which genes are regulated reciprocally by 
the switch between both factors that is described in this manuscript. 
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These differences could reside in the sequence motifs of the 
corresponding promoters or be mediated by the binding of additional 
protein factors. Our data are thus a contribution to uncover how Rac1 
signalling shapes gene expression and how the deregulation of Rac1 
activity that is observed for example in cancer (Sahai and Marshall, 2002) 
promotes cell proliferation. 
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3.8. Supplementary Data  
 
Supplementary Figure S3.1. Analysis of protein complex formation between 
the transcription factors STAT5A and BCL-6. DLD-1 cells were co-transfected 
with STrEP-tagged BCL-6 or STrEP empty vector and either pEGFP-STAT5A or 
pEGFP-PAK1 (IP positive control; see Barros et al., 2009). After 16 h of 
expression cells were lysed in non-denaturing lysis buffer and extracts incubated 
with streptavidin-agarose (Sigma) to precipitate BCL-6. Beads were washed 5x 
with an excess of lysis buffer and the precipitated protein complexes analysed by 
Western blot as indicated. Note that the experimental conditions allowed the 
detection of the complex formed between BCL-6 and PAK1; however, no 
interaction was observed between BCL-6 and STAT5A. Lack of interaction 
between both factors assures that the changes in promoter occupancy observed 
in Figures 3.3B, 3.7 and 3.8 reflect true switching between BCL-6 and STAT5 
rather than an interaction between both proteins at the promoter that could 
interfere with recognition by their specific ChIP antibodies. 
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Supplementary Figure S3.2. Semi-quantitative RT-PCR to document the 
efficiency of the indicated gene depletions. Cells were transfected as indicated 
and lysed following 48 h for RNA extraction. Semi-quantitative RT-PCR was used 
to document the efficiency of the respective gene depletions. RNA polymerase II 
(Pol II) was amplified as a control gene and two serial dilutions of scramble siRNA 
(siCtrl) served to assure semi-quantitative PCR conditions and estimate 
knockdown efficiency. MW= 100 bp molecular weight marker. (A) DLD-1 and 
HT29 cells were transfected with either scramble control (siCtrl), or BCL-6  
(siBCL-6) or STAT5A-specific (siSTAT5A) siRNA oligonucleotides. Note the 
levels of specific depletion of BCL-6 and STAT5A (lanes 1 and 6, respectively). 
(B) DLD-1, SW480 and HT29 cells were transfected with either control or PAK1 
(siPAK1)-specific oligos. Serial dilutions of a mixture (mix) of the three cell lysates 
following transfection with scramble siRNA (siCtrl) served to estimate knockdown 
efficiency specific PAK1 depletion is evident in lanes 2 and 6.  
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Supplementary Table S3.1. List of primers and PCR conditions. (F* – 
forward, R* – reverse; Ta – Annealing temperature)    
 
Primer name Sequence Ta ºC Cycles 
Primers used to clone STAT5A cDNA  
STAT5A-F* 5’ATGGCGGGCTGGATTCAGG 
STAT5A-R* 5’ATCTCAGGACAGGGAGCTTCT 62 35 
Primers used for qPCR amplification of gene transcripts 
(10 min at 95ºC, then 40 cycles of 15 sec at 95ºC and 30 sec at 60ºC) 
CCND2-F* 5’GCCATCTGTGGGCTCCAGCA 
CCND2-R* 5’AGGGGTGCTGGCTTGGTCCA 60 40 
    CDKN2B-F* 5’CTGCGGAATGCGCGAGGAG 
CDKN2B-R* 5’TCATGACCTGGATCGCGCG 60 40 
    SUMO1-F* 5’AAGTGACGCGAGGCGTAGCG 
SUMO1-R* 5’AGGTTTTGCCTCCTGGTCAGACA 60 40 
 
 
   PGK1-F* 5’CAGTTTGGAGCTCCTGGAAG 
PGK1-R* 5’CACTGCACCCTGGATTTGCA 60 40 
    Pol II-F* 5’CGCAATGAGCAGAACGGCGC 
Pol II-R* 5’TCTGCATGGCACGGGGCAAG 60 40 
Primers used for promoter amplification following ChIP  
(5 min at 94ºC, 30 s at 94ºC, 30 s at Ta, 15 s at 72ºC and 5 min at 72ºC) 
BCL-6 reporter    
pGL3-ChIP-F* 5’CGAGCTCTTACGCGTGCTA 
pGL3-ChIP-R* 5’CCTCGGCCTCTGCATAAATA 62 27 
CCND2 promoter    
CCND2-ChIP-F* 5’GTATCTCCTGTAAAGACAGCC 
CCND2-ChIP-R* 5’CCTGCATCTGCTGACAAGC 62 35 
CDKN2B promoter    
CDKN2B-ChIP-F* 5’GATGCCACTCATTCCCTTCTAC 
CDKN2B-ChIP-R* 5’ATGGCTCACCTCACAGCACACC 62 35 
SUMO1 promoter    
SUMO1-ChIP-F* 5’TCAGTCGTCAGAGACGCGCAA 
SUMO1-ChIP-9R* 5’ACAACACCGCGGCTGCAGTAA 62 35 
Negative control    
MUTYH-ChIP-F* 5’GGGACTGACGGGTGATCTCT  
MUTYH-ChIP-R* 5’AGAGGGGCCAAAGAGTTAGC 62 35 
Primers used for semi-quantitative transcript amplification  
(5 min at 94ºC, 30 s at 94ºC, 30 s at Ta, 30 s at 72ºC and 5 min at 72ºC) 
BCL-6-F* 5’AGAGCCCATAAAACGGTCCT 
BCL-6-R* 5’AGTGTCCACAACATGCTCCA 62 30 
    STAT5A-F* 5’GCCATTGACTTGGACAATCC 
STAT5A-R* 5’AGCTGCAATTGTTGGCTTCT 62 30 
    PAK1-F* 5’GTCAGCTGAGGATTACAATTC 
PAK1-R* 5’GAGATGTAGCCACGTCCCGAG 56 28 
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 The Rac1/PAK1 kinase signalling axis has been implicated in the 
transduction of extracellular signals regulating a diverse array of cellular 
processes that include cell proliferation, cell survival, cytoskeleton 
remodelling and gene expression (reviewed in Bokoch, 2003; Bosco et al., 
2009). Not surprisingly, given their critical roles in cell regulation, the 
expression and activity of Rac1 and PAK1 have been often found 
deregulated in several human pathologies, including cancer (reviewed in 
Bosco et al., 2009; Dummler et al., 2009; Ong et al., 2011). Their 
association with tumorigenesis, in particular, has placed these molecules 
in the spotlight as potential therapeutic targets for several cancer types. In 
fact, a strong effort has been made in recent years towards the 
development of specific and selective Rac and PAK inhibitors with 
pharmacological application (Gao et al., 2004; Désiré et al., 2005; Deacon 
et al., 2008; Crawford et al., 2012). Some of these molecules have proven 
to be specific and quite useful for research purposes (see Chapter 2     
and 3) and a few are currently progressing to clinical development 
(Crawford et al., 2012).  
 Indeed, in the past decade, we have assisted to a remarkable 
revolution in the field of cancer therapy with the introduction of molecular 
targeted therapy and the widespread development of specific inhibitors to 
signalling molecules. This progress in cancer therapeutic drugs was 
mainly motivated by the concept of “oncogene addiction” that postulates 
that some cancers apparently depend on one or a few oncogenic proteins 
for the maintenance of the malignant phenotype, despite the probable 
accumulation of multiple alterations that contributed to the tumorigenic 
process. Numerous studies have supported this concept and shown that 
in certain tumours, inactivation of a single oncogene was sufficient to 
inhibit the growth and survival of cancer cells. So far, the clinical success 
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of this approach was mainly achieved by drugs that target oncogenic 
protein kinases. One hallmark example is the inhibitor imatinib developed 
against the BCR/ABL fusion protein that characterizes chronic myeloid 
leukemia and caused complete remission in many patients. However, in 
many cases drug resistance occurred and required new treatment with 
modified inhibitors (Weinstein and Joe, 2008; McCormick, 2011; 
Settleman, 2012). Other examples are the inhibitors of the 
Ras/RAF/MEK/ERK signalling pathway, which revealed a problem with 
targeting such pleiotropic factors, due to the high potential for systemic 
adverse side effects (Mitwally, 2007; Winther and Olsen, 2011; Lee et al., 
2012) and occurrence of  drug resistance  (Poulikakos and Solit, 2011; 
Trujillo, 2011).  
 In effect, while the concept of increasing treatment specificity by 
directing it to a specific oncogenic target protein emerged as very 
promising, few cases have been successful in the clinic (Levitzki and 
Klein, 2010; Logue and Morrison, 2012).  One of the main problems is that 
cancer cells respond to chronic drug treatment by either selecting mutant 
clones that are resistant or by adapting their signalling circuitry, taking 
advantage of pathway redundancy and routes of feedback and cross-talk 
to maintain their function. A new paradigm is now emerging that 
emphasizes the need to confront a complicated disease such as cancer 
from a signalling network perspective, taking into account how effector 
molecules and signalling pathways interconnect and adapt (Logue and 
Morrison, 2012). One recent example is the so-called BRAF paradox. The 
Ras/RAF/MEK/ERK signalling pathway is frequently deregulated in 
cancer, as a result of activating mutations in the BRAF and RAS genes. 
Oncogenic BRAF mutations generally bypass the need for Ras binding 
and promote constitutive BRAF activation and thus of ERK (Hatzivassiliou 
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et al., 2010; Heidorn et al., 2010; Poulikakos and Solit, 2011). The most 
frequent BRAF mutant (BRAF-V600E) is found in 50% of malignant 
melanomas as well as in many colorectal and thyroid cancers (Dhomen 
and Marais, 2007; Cantwell-Dorris et al., 2011) and occurs in a mutually 
exclusive manner with Ras mutations (Heidorn et al., 2010). Intriguingly, 
the use of a specific BRAF inhibitor showed, in some patients, a 
contradictory increase in ERK signalling and tumour progression. Later, it 
was found that the action of this inhibitor depended on the cellular context. 
Thus, in tumours with BRAF-V600E mutation the inhibitor effectively 
blocks ERK activation. On the contrary, in tumours harbouring oncogenic 
Ras, it was found that BRAF-wt and CRAF form a dimer localized with 
Ras at the membrane and that binding of the inhibitor to BRAF stabilized 
dimer formation and enhanced CRAF activation, which stimulated ERK 
signalling and tumour cell proliferation (Hatzivassiliou et al., 2010; Heidorn 
et al., 2010; Poulikakos and Solit, 2011). An accumulating body of clinical 
trial-associated evidence has demonstrated the importance of 
understanding the detailed regulatory mechanisms involved in signal 
transduction in order to design the best possible, tumour-tailored 
therapeutic strategy. Several studies reported that the combined use of 
multiple drugs, targeting different key players in pertinent signalling 
pathways can overcome the redundancy and increase treatment 
effectiveness, reducing the effective drug dosage and therapy duration, 
lowering toxicity and preventing acquired resistance (Fitzgerald et al., 
2006; Logue and Morrison, 2012).  
 Such issues may also condition the use of Rac1 or PAK1-based 
therapies and hence the end term purpose of the work here presented. 
Our results provide new data on how the deregulation of Rac1 and PAK1 
signalling can contribute to the tumorigenic process in colorectal cancers. 
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A novel pathway was described in which Rac1 inhibits the activity of the 
transcriptional repressor BCL-6 through PAK1-mediated phosphorylation. 
This inhibition was shown to be physiological meaningful, affecting the 
expression levels of BCL-6 target genes, like NFKB1 and CD44 (see 
Chapter 2). Moreover, Rac1 was shown to activate gene transcription by 
inducing a switch from repressor BCL-6 to activator STAT5 at the 
promoter of cell-cycle-associated target genes. CCND2, CDKN2B and 
SUMO1 were thus identified as inversely regulated by BCL-6 and STAT5 
and shown to respond to Rac1 and PAK1 signalling with an increase in 
their transcript levels (see Chapter 3). Moreover, this was the first time 
that this STAT5/BCL-6 transcriptional switch was demonstrated in 
epithelial cells and, more importantly, that this switch is under the control 
of Rac1 signalling (see Chapter 3). Recently, another example of 
transcription factor switching at a shared promoter binding site was 
described (Wozniak et al., 2012). 
 Further studies are now required to clarify the impact and 
significance of the novel mechanism characterized in this work for 
tumorigenesis. Is this mechanism specific for colorectal cells, or does it 
also condition gene expression in other cell types? What is the full 
spectrum of target genes modulated by this switch? What other cellular 
functions, besides cell cycle regulation, are modulated by this pathway? 
Can these be targeted along with Rac1 and PAK1 in cancer to avoid 
redundancy and resistance? Can the target genes of this pathway help us 
to generate better tumour profiles? Can they be used as new tumour 
biomarkers, and guide choices for combinatorial drug therapies, targeting 
these and other signalling pathways and molecules?  
Work is ongoing in the host research group to perform a genome-
wide study to identify the target genes of the Rac1/PAK1/BCL-6 and 
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Rac1/STAT5 pathways. This study will involve the use of the ChIP-Seq 
technique that combines the traditional ChIP with deep sequencing. In this 
way, the DNA fragments bound by either STAT5 or BCL-6 are enriched 
and then systematically sequenced, providing sequence readouts that will 
be aligned to the human genome to identify the candidate target genes 
and statistically relevant protein binding sites (Dowell, 2010; Kim and 
Park, 2011). With a list of target genes the research options increase, and 
several of the questions above can start to be addressed. It is currently 
clear that patient profiling will be critical for determining the most suitable 
targets and subsequent lines of a combinatorial treatment and that 
monitoring of tumours at the signalling level during treatment will be 
required to achieve a durable response. The ultimate goal of this study is 
that the novel signalling pathway and the transcriptional switch 
characterized in this thesis can, in the future, provide useful tools for this. 
Moreover, we anticipate that once characterized, some or several of the 
pathway target genes can be used in combination with Rac/PAK and, 
possibly, other pathway inhibitors to impose a series of signalling blocks 
that cannot be overcome, thus effectively eradicating the targeted cancer. 
In conclusion, we believe this thesis work contributes with new 
insights on how deregulation of Rac1 signalling affects the cell’s 
transcriptome and opens new directions for research and therapeutic 
intervention.  
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